Biobetter reagents for blood typing : studies on the properties of agglutinating mouse IgG3 and IgM antibodies by Klaus, Tomasz
 
 
Uniwersytet Jagielloński w Krakowie 
Wydział Biochemii, Biofizyki i Biotechnologii 
 
 
 
 
Praca doktorska 
Innowacyjne odczynniki do diagnostyki grup krwi. 
Badanie właściwości mysich przeciwciał IgG3 oraz IgM  
wywołujących hemaglutynację. 
 
Tomasz Klaus 
 
 
 
 
Promotor 
prof. dr hab. Joanna Bereta 
 
2019
2 
 
Tytuł w języku angielskim:  
Biobetter reagents for blood typing. Studies on the properties of agglutinating mouse IgG3 and IgM 
antibodies.  
3 
 
W skład niniejszej rozprawy doktorskiej wchodzą trzy publikacje: 
 
Agglutinating mouse IgG3 compares favourably with IgMs in typing of the blood group B antigen: 
Functionality and stability studies. Klaus T, Bzowska M, Kulesza M, Kabat AM, Jemioła-Rze-
mińska M, Czaplicki D, Makuch K, Jucha J, Karabasz A, Bereta J. Sci Rep. 2016 Aug 3;6:30938. 
 
Mouse Antibody of IgM Class is Prone to Non-Enzymatic Cleavage between CH1 and CH2 Do-
mains. Klaus T, Stalińska K, Czaplicki D, Mak P, Skupien-Rabian B, Kedracka-Krok S, Wiatrow-
ska K, Bzowska M, Machula M, Bereta J. Sci Rep. 2018 Jan 11;8(1):519.  
 
CH2 Domain of Mouse IgG3 Governs Antibody Oligomerization, Increases Functional Affinity to 
Multivalent Antigens and Enhances Hemagglutination. Klaus T, Bereta J. Front Immunol. 2018 
May 23;9:1096. 
 
Opis mojego wkładu w przygotowanie wyżej wymienionych publikacji oraz ich przedruki znajdują 
się na końcu niniejszego opracowania.  
4 
 
Spis treści 
 
Streszczenie ...................................................................................................................................... 5 
Abstract ............................................................................................................................................. 6 
Opis celów, najważniejszych wyników i wyciągniętych wniosków ................................................ 7 
Literatura ........................................................................................................................................ 16 
Opis wkładu w przygotowanie publikacji stanowiących podstawę pracy doktorskiej ................... 18 
Przedruki publikacji stanowiących podstawę pracy doktorskiej .................................................... 20 
 
  
5 
 
Streszczenie 
Przeciwciała IgM pełnią kluczową rolę w humoralnej odpowiedzi immunologicznej. Cząsteczki te 
ze względu na swoje właściwości stały się także przedmiotem zainteresowania przemysłu biotech-
nologicznego. Przeciwciała IgM rozpoznające antygeny powierzchniowe czerwonych krwinek wy-
wołują hemaglutynację. Reakcja ta polega na zlepianiu krwinek w agregaty i pozwala szybko oce-
nić obecność danego antygenu na krwinkach. Dzięki swoim właściwościom przeciwciała IgM są 
szeroko wykorzystywane w diagnostyce grup krwi. Ponadto ze względu na wysoki potencjał cyto-
toksyczny postrzega się je również jako bioterapeutyki nowej generacji, które w przyszłości mogą 
zostać użyte m.in. w leczeniu nowotworów. 
Przeciwciała IgM są oligomerami o masie cząsteczkowej sięgającej 1 MDa z bogatą glikozylacją 
i dziesiątkami mostków disiarczkowych. Złożona budowa sprawia, że przeciwciała IgM są niesta-
bilne, szybko tracą aktywność i trudno je produkować. Cechy te w konsekwencji negatywnie wpły-
wają na jakość odczynników diagnostycznych opartych na przeciwciałach IgM. 
W swojej pracy doktorskiej badałem przyczyny niestabilności przeciwciał IgM oraz starałem się 
opracować odczynniki diagnostyczne o poprawionej trwałości. Moje badania dotyczyły mysich 
przeciwciał monoklonalnych, które są powszechnie wykorzystywane do oznaczania antygenów 
układu grupowego ABO. 
Jednym z najważniejszych osiągnięć mojej pracy było scharakteryzowanie nieznanego dotych-
czas sposobu degradacji mysich przeciwciał IgM polegającego na nieenzymatycznej proteolizie. 
Na podstawie otrzymanych wyników zaprojektowałem i uzyskałem zmutowane przeciwciała IgM, 
które nie ulegały opisanej przeze mnie fragmentacji i cechowały się zwiększoną stabilnością. 
Ponadto nasz zespół nieoczekiwanie uzyskał aglutynujące mysie przeciwciała IgG3. Przeprowa-
dzone przeze mnie analizy wykazały, że są one znacznie stabilniejsze niż przeciwciała IgM i mogą 
stać się atrakcyjną alternatywą dla stosowanych obecnie odczynników diagnostycznych do ozna-
czania grup krwi. 
Przeciwciała IgG były dotychczas postrzegane jako zbyt małe, by móc jednocześnie związać anty-
geny na dwóch czerwonych krwinkach i wywołać hemaglutynację. W swojej pracy wykazałem 
jednak, że przeciwciała IgG3, jako jedyne spośród czterech podklas mysich IgG, wywołują hema-
glutynację w bardzo niskich stężeniach. To odkrycie zachęciło mnie do próby wyjaśnienia mecha-
nizmu hemaglutynacji zależnej od IgG3. Zbadałem wpływ poszczególnych domen mysich prze-
ciwciał IgG3 na ich zdolność do hemaglutynacji, oligomeryzacji i wiązania poliwalentnych 
antygenów z wysokim powinowactwem. 
Uzyskane w ramach pracy zmutowane przeciwciała IgM oraz przeciwciała IgG3 są dwoma rodza-
jami innowacyjnych odczynników diagnostycznych o poprawionej stabilności.   
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Abstract 
Antibodies of IgM class play a crucial role in humoral immunity. The properties of IgM are also 
within the interest of biotech industry. IgMs specific to a particular antigen present on the surface 
of erythrocytes trigger hemagglutination. This reaction of erythrocyte aggregation enables rapid 
identification of antigens present on the cells. Thus, IgMs are commonly used in blood typing. 
Moreover, IgMs are considered as next generation biotherapeutics that may be useful in cancer 
treatment because of their high cytotoxic potential. 
IgM is a heavily glycosylated oligomer with a molecular mass of about 1 MDa and it contains 
dozens of disulfide bonds. The complex structure of IgM adversely affects its stability and produc-
tivity. IgMs usually rapidly lose their activity during storage. Consequently, the quality of IgM-
based diagnostic reagents is decreased. 
In my PhD project I investigated the stability of IgM molecules and I developed IgM- and IgG3-
based biobetter reagents with improved durability. The subject of my project were mouse antibod-
ies, which are worldwide used for typing of ABO blood group antigens. 
One of the achievements of my project was a discovery of a new non-enzymatic pathway of 
mouse IgM degradation. Based on my results I designed and generated mutated IgMs that were 
resistant to the discovered degradation pathway. These antibodies had increased stability in com-
parison to parental IgMs. 
Moreover, our team unexpectedly obtained agglutinating mouse IgG3 molecules that were more 
stable than IgMs. In the light of the results of my experiments, the IgG3 molecules may become 
an attractive alternative to the currently used reagents for blood typing. 
According to the general opinion, antibodies of IgG class cannot trigger hemagglutination because 
they are too small to simultaneously bind antigens on two erythrocytes. However, in my experi-
ments I proved that IgG3s elicit hemagglutination even at a very low concentration. In contrast, 
other mouse IgG subtypes did not agglutinate erythrocytes. This discovery encouraged me to in-
vestigate a mechanism of IgG3-dependent hemagglutination. I elucidated how particular do-
mains of mouse IgG3 influence hemagglutination, antibody oligomerization and affinity 
to polyvalent antigens. 
The developed IgG3 molecules and mutated IgMs are two types of innovative blood typing reagents 
with improved stability.  
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Opis celów, najważniejszych wyników i wyciągniętych wniosków 
Cele pracy 
Przeciwciała, nazywane inaczej immunoglobulinami (Ig), są białkami produkowanymi przez lim-
focyty B. Stanowią one kluczowy oręż odporności swoistej wykorzystywany do zwalczania pato-
genów. Przeciwciała pełnią podwójną funkcję w odpowiedzi immunologicznej, co znajduje od-
zwierciedlenie w ich budowie (Rysunek 1). Część zmienna przeciwciał specyficznie wiąże się z an-
tygenem, a część stała aktywuje mechanizmy obronne, tzw. funkcje efektorowe przeciwciał, które 
pozwalają na eliminację zagrożenia.  
Przeciwciała są powszechnie wykorzystywane w badaniach naukowych, diagnostyce, transplanto-
logii, a także w terapiach, zwłaszcza chorób nowotworowych i schorzeń o podłożu zapalnym. 
Ostatnio coraz więcej uwagi poświęca się modyfikacjom przeciwciał w celu poprawy efektywności 
ich działania. 
Przeciwciała wiążą się z określonym antygenem, dzięki czemu mogą służyć do jego wykrywania. 
Przykładem zastosowania przeciwciał jest diagnostyka grup krwi. Grupy krwi oznacza się metodą 
hemaglutynacji. Polega ona na zmieszaniu kropli badanej krwi z kroplą odczynnika zawierającego 
przeciwciała monoklonalne rozpoznające dany antygen grupowy, np. antygen A układu ABO. Jeśli 
na powierzchni czerwonych krwinek jest obecny badany antygen, to w ciągu kilku minut pod wpły-
wem przeciwciał dochodzi do widocznego gołym okiem zlepiania się krwinek. Proces ten, okre-
ślany jako aglutynacja, pozwala na identyfikację antygenu obecnego na powierzchni krwinek, a 
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Rysunek 1 – Porównanie budowy przeciwciał IgG i IgM. Każde przeciwciało składa się z łań-
cuchów lekkich (L, szary) i ciężkich (H, czarny), które są osobnymi łańcuchami polipeptydowymi. 
Deseniem wyróżniono części zmienne (VH, VL) odpowiedzialne za wiązanie się do określonego 
antygenu. Fc – fragment odpowiedzialny za funkcje efektorowe przeciwciał. Okręgiem wskazano 
region zawiasowy w cząsteczce IgG. CH1, CH2, CH3 – domeny części stałej łańcucha ciężkiego, 
CL – część stała łańcucha lekkiego. 
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tym samym na oznaczenie grupy krwi (Rysunek 2). Testy diagnostyczne oparte na hemaglutynacji 
zapewniają bezpieczeństwo leczenia krwią, a dzięki swojej prostocie oraz szybkości uzyskania wy-
niku są doskonałą techniką w sytuacjach zagrożenia życia, np. gdy pacjent uległ wypadkowi i wy-
maga natychmiastowego podania krwi. 
Ze względu na zróżnicowanie budowy i funkcji przeciwciał, białka z tej rodziny zostały podzielone 
na kilka klas, wśród których wyróżnić można m.in. immunoglobuliny M (IgM) oraz immunoglo-
buliny G (IgG) (Rysunek 1). Przeciwciała używane w diagnostyce grup krwi należą do klasy IgM. 
Są to duże cząsteczki, w których odległość między miejscami wiązania antygenu sięga 35 nm [1]. 
Przeciwciała IgM wywołują silną aglutynację, ponieważ bez trudu są w stanie związać antygeny 
na dwóch erytrocytach, w wyniku czego dochodzi do zlepiania krwinek [2] (Rysunek 2). 
 
 
Przeciwciała IgM mają bardzo złożoną budowę. Są najczęściej penta- lub heksamerami o masie 
cząsteczkowej około 1 MDa. Białka te mają w swojej strukturze dziesiątki mostków disiarczko-
wych i są bardzo bogato glikozylowane. Złożona struktura przeciwciał IgM powoduje, że są one 
produkowane z niską wydajnością i są niestabilne w trakcie przechowywania [3,4]. Z tego powodu 
odczynniki diagnostyczne zawierające przeciwciała IgM szybko tracą aktywność. Molekularne 
przyczyny braku stabilności przeciwciał IgM oraz ścieżki ich degradacji w odczynnikach diagno-
stycznych dotychczas nie były znane. 
W pracy doktorskiej badałem stabilność mysich przeciwciał IgM rozpoznających antygen 
B ludzkiego układu grupowego ABO. Celem było zidentyfikowanie mechanizmu degradacji 
przeciwciał IgM w odczynnikach diagnostycznych. Kolejnym krokiem było opracowanie me-
tody zapobiegania degradacji przeciwciał IgM w trakcie ich przechowywania. 
Rysunek 2 – Aglutynacja erytrocytów przez przeciwciała klasy IgM.  A – niezaglutynowane 
erytrocyty w zawiesinie, B – makroskopowy wygląd zaglutynowanych czerwonych krwinek. Ry-
sunek nie jest wykonany w skali, średnica przeciwciał IgM (35 nm) jest około 200 mniejsza niż 
średnica czerwonych krwinek (6 μm). 
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Zgodnie z wiedzą podręcznikową przeciwciała IgG nie wywołują aglutynacji czerwonych krwinek 
[2,5]. Zasięg części wiążących antygen w przeciwciałach IgG nie przekracza 15 nm [6] i jest mniej-
szy niż minimalna odległość na jaką mogą zbliżyć się do siebie erytrocyty w warunkach fizjolo-
gicznych [7] (Rysunek 1). Dlatego powszechnie uważa się, że przeciwciała IgG są za małe, żeby 
wywołać aglutynację. 
Nasz zespół nieoczekiwanie wyselekcjonował komórki hybrydoma produkujące unikalne mysie 
przeciwciało IgG3 rozpoznające antygen B, które aglutynowało czerwone krwinki z wydajnością 
porównywalną do przeciwciał IgM [8]. Uzyskane przeciwciało IgG3 było ponadto bardzo stabilne. 
Jego właściwości wskazywały, że mogłoby ono stanowić doskonały zamiennik przeciwciał IgM 
w testach hemaglutynacji. W swojej pracy doktorskiej dokładnie scharakteryzowałem to przeciw-
ciało i zbadałem strukturalne podstawy jego niezwykłych właściwości. 
IgG3 to jedna z czterech podklas przeciwciał IgG u myszy. Pozostałe trzy noszą odpowiednio na-
zwy: IgG1, IgG2a oraz IgG2b. Podklasa IgG3 jest najsłabiej poznanym typem mysich przeciwciał 
i wykazuje liczne, unikalne wśród wszystkich immunoglobulin właściwości. Mysie IgG3 wyróż-
niają się zdolnością do odwracalnej precypitacji w niskich temperaturach –  tworzą tzw. krioglobu-
liny [9]. Immunoglobuliny te oddziałują ponadto ze sobą poprzez części stałe i w efekcie oligome-
ryzują [10]. Przeciwciała IgG3 wiążą także poliwalentne antygeny ze zwiększonym powinowac-
twem w porównaniu do innych podklas [10,11]. Prawdopodobnie dzięki tym cechom IgG3 wyjąt-
kowo skutecznie zwalczają zakażenia bakteryjne [12,13]. Te same właściwości wydają się być jed-
nak również przyczyną poważnych reakcji autoimmunologicznych [14]. Dotychczasowe badania 
nie pozwoliły jednoznacznie wyjaśnić, dlaczego mysie IgG3 oligomeryzują i tworzą krioglobuliny 
[15–17]. Nasze odkrycie, że przeciwciała IgG3 wywołują wydajną hemaglutynację dodatkowo po-
twierdziło ich unikalny charakter [8].  
Drugim celem mojej pracy doktorskiej było zbadanie molekularnych mechanizmów homoty-
powych i heterotypowych oddziaływań przeciwciał IgG3. Starałem się znaleźć związek mię-
dzy strukturą przeciwciał IgG3 a ich właściwościami. Chciałem zidentyfikować domeny od-
powiadające za zdolność IgG3 do oligomeryzacji, hemaglutynacji i wiązania poliwalentych 
antygenów z wysokim powinowactwem. 
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Uzyskane wyniki 
Badania dotyczące stabilności mysich przeciwciał IgM 
Na etapie formulacji odczynników diagnostycznych nasz zespół obserwował, że mysie przeciw-
ciała IgM szybko tracą aktywność w trakcie przechowywania i są szczególnie wrażliwe na pod-
wyższoną temperaturę (37-42 °C) [8]. Wyniki te były zgodne z doniesieniami innych autorów, choć 
dokładne przyczyny braku stabilności przeciwciał IgM nie były znane [3,4]. 
Wykonane przeze mnie analizy wykazały, że w trakcie przechowywania przeciwciał IgM zachodzą 
dwa procesy: agregacja i proteoliza [8]. Powstające agregaty były podatne na działanie czynników 
redukujących. Wynik ten wskazuje, że agregacja przeciwciał IgM jest przede wszystkim efektem 
reorganizacji mostków disiarczkowych. Każdorazowo wykrywałem także niewielką ilość nieredu-
kowalnych agregatów, co może świadczyć o współistnieniu innego mechanizmu agregacji IgM, 
np. zależnego od reaktywnych grup aminowych. 
Bardzo interesującym zjawiskiem była postępująca proteoliza łańcucha ciężkiego IgM w trakcie 
przechowywania odczynnika [8]. Obserwowałem przyrost skróconej formy łańcucha ciężkiego 
IgM (określanej w literaturze jako łańcuch μ’). Łańcuch μ’ został odkryty przez Marksa i Bosmę 
w 1985 r., jednak pochodzenie tego polipeptydu nie było znane [18]. Moje wyniki wskazywały, 
że łańcuch ten powstaje pozakomórkowo, w procesie proteolizy. 
W celu poznania sekwencji łańcucha μ’ wyizolowałem go z trzech różnych przeciwciał IgM. Uzy-
skane łańcuchy μ’ zostały następnie poddane analizom przy użyciu spektrometrii mas oraz sekwen-
cjonowaniu Edmana. Dzięki tym doświadczeniom zlokalizowałem wiązanie peptydowe po reszcie 
asparaginy 209 (Asn209), którego przecięcie skutkuje utworzeniem łańcucha μ’ [19]. Wykorzystu-
jąc mutagenezę punktową dowiodłem, że Asn209 jest kluczowa w badanym procesie proteolizy 
[19]. Wymiana Asn209 na dowolną inną resztę aminokwasową zapobiegała fragmentacji łańcucha 
ciężkiego w mysich przeciwciałach IgM. 
Reszta Asn209 poprzedza łącznik między domenami CH1 i CH2 łańcucha ciężkiego. Zerwanie 
wiązania peptydowego w tym miejscu skutkuje odłączeniem fragmentu wiążącego antygen (Fab). 
W efekcie przeciwciało IgM traci Fab i zmniejsza się jego walentność (Rysunek 3). Obecność łań-
cucha μ’ potwierdziłem także w mysiej surowicy, co wskazuje, że proces skracania przeciwciał 
IgM prawdopodobnie zachodzi in vivo i może mieć poważne konsekwencje fizjologiczne [8]. 
Starałem się również zidentyfikować czynnik odpowiedzialny za proteolizę po Asn209. Odczyn-
niki do diagnostyki grup krwi są preparatem przeciwciała, który uzupełniony jest m.in. dużą ilością 
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białka nośnikowego np. surowicy grupy AB lub albuminy bydlęcej. Moje doświadczenia wskazy-
wały, że czynnik powodujący proteolizę łańcucha ciężkiego IgM zawarty jest w surowicy oraz 
w jej frakcjach wzbogaconych w albuminę [8]. Nie wykrywałem łańcucha μ’ w lizatach komórko-
wych linii hybrydoma produkujących przeciwciała IgM, ani nie obserwowałem przyrostu jego ilo-
ści w roztworze czystego przeciwciała IgM. 
Przeprowadziłem liczne analizy z użyciem inhibitorów proteaz, jednak dały one niejednoznaczne 
wyniki [19]. Badanie wpływu inhibitorów na przecinanie IgM miało umożliwić identyfikację klasy 
proteazy odpowiadającej za ten proces. Żaden z zastosowanych pojedynczych inhibitorów nie ha-
mował fragmentacji IgM. Przecinanie IgM było hamowane wyłącznie przez koktajl inhibitorów, 
ale efekt ten prawdopodobnie był wynikiem wzmożonej agregacji przeciwciał IgM w obecności 
koktajlu inhibitorów. Sprawdziłem również zależność proteolizy po Asn209 od pH. Proteoliza łań-
cucha ciężkiego IgM wydajnie zachodziła w pH obojętnym i alkalicznym, a w niskim pH ulegała 
zahamowaniu [19]. 
Wykorzystując dostępne bazy danych poszukiwałem proteaz, które trawią białka po reszcie aspa-
raginy. Zidentyfikowałem potencjalny enzym mogący być czynnikiem fragmentującym przeciw-
ciała IgM – była to legumaina (proteaza cysteinowa). Eksperymenty z inhibitorami legumainy oraz 
z działaniem rekombinowaną legumainą na przeciwciała IgM wykluczyły jednak udział tego en-
zymu we fragmentacji przeciwciał IgM [19]. 
Próby identyfikacji czynnika fragmentującego przeciwciała IgM obejmowały także frakcjonowa-
nie surowicy i pożywek po hodowli komórek wątrobiaka (linia Hep G2), które produkują większość 
białek osocza. Następnie sprawdzano, które z uzyskanych frakcji wywołują fragmentację przeciw-
ciał IgM. Doświadczenia te wskazywały, że nie ma jednego czynnika skracającego łańcuch ciężki 
IgM [19]. Wykonane później analizy stabilności przeciwciał IgM w obecności białek o różnym 
Rysunek 3 – Fragmentacja mysiego przeciwciała IgM. A – Niezdegradowane przeciwciało IgM. 
B – Przeciwciało IgM zawarte w odczynniku diagnostycznym ulega nieenzymatycznej fragmenta-
cji prowadzącej do utraty fragmentów Fab. Proces ten postępuje w czasie. C – Przeciwciało IgM 
po długim okresie przechowywania ma zmniejszoną walentność. 
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punkcie izoelektrycznym wykazały, że obserwowana fragmentacja zależy od obecności kwaśnych 
białek i nie jest typowym procesem enzymatycznym [19]. Dokładny mechanizm odkrytego zjawi-
ska niestety nie został w całości wyjaśniony. 
Podsumowując w ramach swojej pracy doktorskiej opisałem nieznany wcześniej sposób nieenzy-
matycznej obróbki proteolitycznej przeciwciał IgM. Odkryty proces zależy od Asn209, pH i obec-
ności kwaśnych białek. Jest on źródłem łańcucha μ’ w mysich przeciwciałach IgM. Uzyskałem 
ponadto różne warianty przeciwciał IgM odpornych na fragmentację, które mają zwiększoną sta-
bilność w porównaniu do niezmutowanych cząsteczek. 
 
Badania dotyczące właściwości mysich przeciwciał IgG3 
W trakcie prowadzonych badań starałem się wyjaśnić molekularne podstawy wyjątkowych właści-
wości mysich przeciwciał IgG3, w szczególności ich zdolności do hemaglutynacji.  
Nasz zespół uzyskał unikalne przeciwciało IgG3 M18, specyficznie rozpoznające antygen B ludz-
kiego układu grupowego ABO [8]. Przeciwciało IgG3 M18 bardzo wydajnie aglutynowało erytro-
cyty mające na swojej powierzchni antygen B. Obserwacja ta przeczyła powszechnemu przekona-
niu, że przeciwciała IgG nie wywołują hemaglutynacji. 
Szczegółowo porównałem odczynnik diagnostyczny oparty na przeciwciele IgG3 z podobnymi od-
czynnikami zawierającymi przeciwciała IgM [8]. Analiza ta wykazała, że przeciwciało IgG3 jest 
znacznie trwalsze i, w przeciwieństwie do przeciwciał IgM, nie traci aktywności w podwyższonej 
temperaturze, ani po zamrożeniu. Przeciwciała IgG3 i IgM wywoływały wydajną hemaglutynację 
w podobnych stężeniach (rzędu 10 μg/ml). Przeciwciała IgG3 były jednak trzykrotnie wydajniej 
produkowane niż przeciwciała IgM przez oryginalne linie hybrydoma. Wykonane przeze mnie ana-
lizy możliwości wykorzystania przeciwciał IgG3 jako odczynników diagnostycznych potwierdziły, 
że cząsteczki te mogą stanowić atrakcyjną pod względem ekonomicznym alternatywę dla przeciw-
ciał IgM. 
Rysunek 4 – Analiza aglutynacji czerwonych krwinek pod wpływem rekombinowanych prze-
ciwciał IgG1, IgG2a, IgG2b i IgG3 wiążących antygen B na ludzkich erytrocytach. Wszystkie 
przeciwciała miały taką samą część zmienną pochodzącą z przeciwciała M18. Przeciwciała w stę-
żeniu około 300 ng/ml inkubowano przez 30 min z zawiesiną ludzkich wzorcowych krwinek grupy 
B. Efekt aglutynacji (formowania agregatów przez czerwone krwinki) oceniano mikroskopowo. 
Rysunek przedstawia reprezentatywny wynik jednego z czterech niezależnych eksperymentów. 
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Poszukiwanie molekularnych przyczyn unikalnych cech przeciwciał IgG3 rozpocząłem od spraw-
dzenia, czy zdolność tych cząsteczek do hemaglutynacji jest konsekwencją wyjątkowego regionu 
zmiennego, czy też wynika z właściwości ich części stałej. W tym celu przygotowałem rekombi-
nowane warianty IgG1, IgG2a, IgG2b oraz IgG3 dwóch różnych przeciwciał rozpoznających anty-
gen B. Jak przedstawiono na Rysunku 4 spośród tych wariantów jedynie przeciwciała IgG3 aglu-
tynowały erytrocyty [8]. Wynik ten wskazywał, że zdolność przeciwciał IgG3 do hemaglutynacji 
zależy od części stałej tego podtypu. 
Następnie starałem się zidentyfikować fragment części stałej przeciwciał IgG3 odpowiadający 
za ich zdolność do hemaglutynacji. Analizy bioinformatyczne sugerowały, że przeciwciała IgG3 
wyróżniają się swoim regionem zawiasowym i że to właśnie ten fragment może determinować ich 
unikalne właściwości [8]. Aby zweryfikować tę hipotezę, przygotowałem model badawczy złożony 
Rysunek 5 - Mutanty domenowe. Przy użyciu metod inżynierii genetycznej przygotowałem wek-
tory kodujące nieistniejące w przyrodzie, chimeryczne przeciwciała. Zidentyfikowanie fragmentu 
kluczowego dla danej aktywności IgG3 polegało na porównaniu właściwości par mutantów ozna-
czonych klamrami. Przedsięwzięcie zakładało, że zmutowane IgG3 utraci swoją właściwość z po-
wodu zastąpienia kluczowego fragmentu sekwencją pochodzącą z IgG1. Jednocześnie zmutowane 
IgG1 powinno nabyć badaną własność IgG3. 
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z hybrydowych przeciwciał (wariantów domenowych) opartych na podtypach IgG1 i IgG3 (Rysu-
nek 5).  
Uzyskane warianty domenowe analizowałem pod kątem ich zdolności do hemaglutynacji. Uzupeł-
nieniem tych doświadczeń było badanie właściwości fragmentów F(ab’)2 otrzymanych dzięki uży-
ciu specyficznych proteaz i technik inżynierii genetycznej. Eksperymenty te wykazały, że choć 
fragment F(ab’)2 IgG3 jest wystarczający do wywołania hemaglutynacji, to jednak działa on znacz-
nie słabiej niż kompletne przeciwciało [8,20]. Na podstawie analizy cech mutantów domenowych 
doszedłem do wniosku, że wydajna hemaglutynacja jest wywoływana przez przeciwciała zawiera-
jące domenę CH2 pochodzącą z podtypu IgG3 [20]. 
Przygotowany model oparty na mutantach domenowych pozwolił mi także na badanie dwóch in-
nych charakterystycznych dla przeciwciał IgG3 właściwości: zdolności do oligomeryzacji oraz 
wiązania poliwalentnego antygenu z wysokim powinowactwem. Jak wykazały moje doświadcze-
nia również te cechy badanych cząsteczek ulegały największym zmianom w wyniku modyfikacji 
domeny CH2.  Wyniki te dowodzą, że domena CH2 jest kluczowa w procesie oligomeryzacji prze-
ciwciał IgG3 i zwiększa ich powinowactwo do poliwalentnych antygenów [20]. 
Bardzo istotnym osiągnięciem mojej pracy było wykazanie, że przeniesienie domeny CH2 mysich 
przeciwciał IgG3 w zrąb podklasy IgG1 umożliwia uzyskanie cząsteczki o cechach typowych dla 
IgG3 [20]. Przeciwciało IgG1 z domeną CH2 pochodzącą z IgG3 oligomeryzowało, wywoływało 
hemaglutynację i wiązało poliwalentny antygen z powinowactwem większym niż wyjściowe prze-
ciwciało IgG1. W swojej pracy doktorskiej po raz pierwszy zademonstrowałem, że poprzez mody-
fikację domeny CH2 możliwe jest uzyskanie przeciwciał o własnościach zbliżonych do mysich 
przeciwciał IgG3. Mysie przeciwciała IgG3 cechują się bardzo wysoką skutecznością zapobiegania 
i zwalczania groźnych chorób bakteryjnych, a ich skuteczność wynika m.in. z ich zdolności do 
oligomeryzacji i wysokiego powinowactwa do poliwalentnych antygenów [12,13]. Wyniki mojej 
pracy otwierają nową możliwość zwiększania skuteczności terapeutycznych przeciwciał poprzez 
modyfikację domeny CH2 w taki sposób, by nadać modyfikowanej cząsteczce właściwości typowe 
dla mysich IgG3. 
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Wnioski 
1. Głównymi mechanizmami degradacji mysich przeciwciał IgM w odczynnikach diagno-
stycznych są nieenzymatyczna proteoliza łańcucha ciężkiego po reszcie Asn209 oraz agre-
gacja wynikająca z rearanżacji mostków disiarczkowych. 
2. Poprawę stabilności mysich przeciwciał IgM można osiągnąć poprzez wymianę reszty 
Asn209 w łańcuchu ciężkim na dowolny inny aminokwas. Taka modyfikacja zapobiega 
nieenzymatycznej proteolizie łańcucha ciężkiego w tych przeciwciałach. 
3. Przeciwciała IgG3 mogą zastąpić przeciwciała IgM w diagnostyce grup krwi. Obie klasy 
przeciwciał cechuje podobna wydajność działania mierzona minimalną ilością przeciw-
ciała (w mikrogramach) potrzebną do wywołania hemaglutynacji. Przeciwciała IgG3 są 
jednak znacznie stabilniejsze i wydajniej syntetyzowane przez komórki niż przeciwciała 
IgM. 
4. Unikalne cechy mysich przeciwciał IgG3 (zdolność do oligomeryzacji, hemaglutynacji 
i wiązania poliwalentnych antygenów z wysokim powinowactwem) silnie zależą od do-
meny CH2. 
5. Cechy typowe dla mysich przeciwciał IgG3 mogą zostać nadane innym podklasom IgG 
poprzez wymianę naturalnej domeny CH2 na homologiczny fragment pochodzący z my-
siego przeciwciała IgG3.  
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Opis wkładu w przygotowanie publikacji stanowiących podstawę pracy doktorskiej 
 
Agglutinating mouse IgG3 compares favourably with IgMs in typing of the blood group B antigen: 
Functionality and stability studies. Klaus T, Bzowska M, Kulesza M, Kabat AM, Jemioła-Rze-
mińska M, Czaplicki D, Makuch K, Jucha J, Karabasz A, Bereta J. Sci Rep. 2016 Aug 3;6:30938. 
W publikacji tej opisano aglutynujące mysie przeciwciało M18 IgG3. Mysie przeciwciała 
IgG3 zostały szczegółowo porównane z mysimi przeciwciałami IgM pod kątem stabilności 
i możliwości ich zastosowania w diagnostyce serologicznej. 
Mój wkład w tę publikację: wykonałem sekwencjonowanie cDNA kodującego przeciw-
ciała i zanalizowałem zebrane dane; zaplanowałem i wykonałem fragmentację przeciwciał 
przy użyciu pepsyny; zaprojektowałem i uzyskałem rekombinowane warianty izotypowe 
przeciwciał M18 i O10; zanalizowałem powinowactwo przeciwciał do antygenu B obec-
nego na erytrocytach; zbadałem stabilność przeciwciał w podwyższonej temperaturze – 
analizy próbek w testach hemaglutynacji i western blotting; przygotowałem próbki do ana-
liz DSC; wykonałem modelowanie molekularne wariantów przeciwciała M18; zwizualizo-
wałem dane uzyskane w modelowaniu i dokonałem pomiarów in silico na przygotowanych 
modelach; określiłem stężenie przeciwciał w mysich surowicach metodą ELISA; uzyski-
wałem komórki hybrydoma poprzez fuzję mysich splenocytów z komórkami szpiczaka 
i sprawdzałem uzyskane klony pod kątem produkcji przeciwciał wywołujących hemaglu-
tynację; przygotowałem wstępną wersję manuskryptu, wraz z pozostałymi autorami prze-
dyskutowałem wyniki i przygotowałem końcową wersję publikacji. 
 
Mouse Antibody of IgM Class is Prone to Non-Enzymatic Cleavage between CH1 and CH2 Do-
mains. Klaus T, Stalińska K, Czaplicki D, Mak P, Skupien-Rabian B, Kedracka-Krok S, Wiatrow-
ska K, Bzowska M, Machula M, Bereta J. Sci Rep. 2018 Jan 11;8(1):519.  
Publikacja ta zawiera opis nieenzymatycznego przecinania łańcucha ciężkiego mysich 
przeciwciał IgM. Opisano w niej identyfikację wiązania peptydowego ulegającego prze-
cięciu oraz wpływ różnych czynników na ten proces, m.in. pH, inhibitorów proteaz, frakcji 
białek produkowanych przez wątrobiaka.  
Mój wkład w tę publikację: zanalizowałem glikozylację IgM; przygotowałem próbki do 
analiz metodą spektrometrii mas i sekwencjonowania N-końca; wykonałem modelowanie 
molekularne domen CH1 i CH2 mysich IgM; zaprojektowałem i uzyskałem wszystkie re-
kombinowane muteiny IgM oraz zanalizowałem ich stabilność wykorzystując metodę we-
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stern blotting; porównałem powinowactwo tych mutein do antygenu obecnego na erytro-
cytach metodą ELISA; poszukiwałem specyficznego inhibitora skracania łańcucha cięż-
kiego IgM; analizowałem stabilność IgM w różnych pH i w obecności białek o różnym pI; 
wykonałem eksperymenty dotyczące legumainy – zbadałem wpływ tego enzymu na prze-
ciwciała IgM, potwierdziłem jego obecność w surowicy, badałem wpływ surowicy z inhi-
bitorami legumainy na przeciwciała IgM; uczestniczyłem w planowaniu wszystkich eks-
perymentów oraz przygotowałem wstępną wersję manuskryptu; po przedyskutowaniu wy-
ników z pozostałymi autorami wraz z autorem korespondencyjnym przygotowałem osta-
teczną wersję publikacji. 
 
CH2 Domain of Mouse IgG3 Governs Antibody Oligomerization, Increases Functional Affinity to 
Multivalent Antigens and Enhances Hemagglutination. Klaus T, Bereta J. Front Immunol. 2018 
May 23;9:1096. 
 Publikacja ta dotyczy związku struktury mysich IgG3 z ich unikalnymi właściwościami. 
Mój wkład w tę publikację: zaprojektowałem i wykonałem wszystkie eksperymenty; za-
projektowałem i uzyskałem wszystkie rekombinowane warianty przeciwciał poddane ana-
lizom, w tym rekombinowane fragmenty przeciwciał; wykonałem analizy powinowactwa 
przeciwciał do antygenu B obecnego na erytrocytach oraz do antygenu B sprzęgniętego 
z albuminą; zbadałem wiązanie składnika dopełniacza C1q do badanych wariantów prze-
ciwciał oraz aktywację kaskady dopełniacza przez te cząsteczki; zanalizowałem zdolność 
do oligomeryzacji wariantów przeciwciał wykorzystując metodę różnicowej precypitacji 
glikolem polietylenowym; przygotowałem wstępną wersję manuskryptu, a następnie po-
prawiałem ją wraz z autorem korespondencyjnym.   
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Agglutinating mouse IgG3 
compares favourably with IgMs 
in typing of the blood group B 
antigen: Functionality and stability 
studies
Tomasz Klaus1,2, Monika Bzowska1,2, Małgorzata Kulesza2, Agnieszka Martyna Kabat2, 
Małgorzata Jemioła-Rzemińska1,2, Dominik Czaplicki2, Krzysztof Makuch2, Jarosław Jucha2, 
Alicja Karabasz2 & Joanna Bereta2
Mouse immunoglobulins M (IgMs) that recognize human blood group antigens induce haemagglutination 
and are used worldwide for diagnostic blood typing. Contrary to the current belief that IgGs are too small 
to simultaneously bind antigens on two different erythrocytes, we obtained agglutinating mouse IgG3 
that recognized antigen B of the human ABO blood group system. Mouse IgG3 is an intriguing isotype that 
has the ability to form Fc-dependent oligomers. However, F(ab′)2 fragments of the IgG3 were sufficient to 
agglutinate type B red blood cells; therefore, IgG3-triggered agglutination did not require oligomerization. 
Molecular modelling indicated that mouse IgG3 has a larger range of Fab arms than other mouse IgG 
subclasses and that the unique properties of mouse IgG3 are likely due to the structure of its hinge region. 
With a focus on applications in diagnostics, we compared the stability of IgG3 and two IgMs in formulated 
blood typing reagents using an accelerated storage approach and differential scanning calorimetry. 
IgG3 was much more stable than IgMs. Interestingly, the rapid decrease in IgM activity was caused by 
aggregation of the molecules and a previously unknown posttranslational proteolytic processing of the μ 
heavy chain. Our data point to mouse IgG3 as a potent diagnostic tool.
Despite many years of research in the field of immunoglobulins, some aspects of antibody biology remain unex-
plained. There is an enormous volume of information concerning the structure and functions of human immu-
noglobulins, with these data mostly being collected during the invention of antibody-based therapeutics. In 
contrast, mouse immunoglobulins are less characterized, although their usefulness in research, diagnostics and 
the generation of genetically engineered chimeric and humanized therapeutics is undeniable1. Substantial dif-
ferences between human and mouse antibodies are evident in the functions and properties of the IgG subclasses 
present in these two species2. Although similar in name, mouse and human IgG subclasses evolved after the 
divergence of the rodent and primate evolutionary lineages3,4; thus, the characteristics of human and mouse IgGs 
are not interchangeable.
Among four subclasses of mouse IgGs: IgG1, IgG2a, IgG2b, and IgG3, the least characterized is the IgG3 iso-
type. IgG3 has the lowest abundance among IgGs in mouse serum. Increased levels of IgG3 have been reported 
after immunization with polysaccharides5 and in autoimmune disorders, e.g., in the mouse model of systemic 
lupus erythaematosus6. In general, mouse IgG3s are able to interact with each other via Fc fragments in the 
absence of cognate antigens7,8. This interaction is very weak, with a KD of approximately 10−4 M9, but its strength 
may be increased by binding certain antigens, especially multivalent antigens10. The exceptional ability of IgG3 
molecules to form non-covalent oligomers is related to their cryoglobulin activity. Cryoglobulins are plasma 
proteins that precipitate reversibly at low temperatures11. The presence of cryoglobulins in serum is strongly 
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correlated with autoimmune disorders6. In mouse models of autoimmunity, IgG3-containing immune complexes 
can induce renal disease and can even lead to death due to acute renal failure12,13. Strait et al.14 recently demon-
strated that IgG1 may protect against the deposition of pathologic antigen-IgG3 antibody complexes in glomer-
ular capillaries14.
Here, we investigated another unique property of mouse IgG3s that are specific towards antigen B from the 
human ABO blood group system. We discovered that the IgG3s obtained in our laboratory induced the aggluti-
nation of erythrocytes. This ability has previously been ascribed only to oligomeric IgMs, in which the distance 
between the two furthermost antigen-binding sites is 35 nm15. IgM induces haemagglutination very strongly and 
efficiently because it can easily bind antigens on two different erythrocytes and form cell aggregates. According 
to the current state of knowledge, IgGs cannot agglutinate red blood cell16. The span of the antigen-binding sites 
of IgG does not exceed 15 nm17 and is smaller than the minimum distance between two erythrocytes under 
physiological conditions. Therefore, it is believed that the IgGs are simply too small to induce haemagglutination.
Contrary to this generally accepted view, we proved that mouse IgG3 induce haemagglutination with sim-
ilar efficacy as IgMs. The features of mouse IgG3 structure that are likely responsible for this ability were ana-
lysed. We also evaluated the applicability of IgG3-based reagents for blood typing and compared the stability 
of IgG3 and IgM in formulations that are used in serological diagnostics. The stability studies revealed a novel, 
protease-dependent, post-secretional processing of mouse IgM. In contrast, IgG3 was not subjected to this pro-
cessing and might serve as a more stable serological reagent.
Results
Unique M18 antibody capable of red blood cell agglutination. We applied the hybridoma technique 
to generate biosimilar reagents suitable for serological diagnostics. The splenocytes of three mice immunized 
with group B red blood cells (RBCs) were used for four independent fusions. Media collected from cultures of 
all of the obtained hybridoma clones were screened for the presence of antibodies using slide agglutination tests 
with RBCs of group A, B and O. Antigens of the ABO blood group system are small, one-epitope oligosaccha-
rides (Supplementary Figure 1)18. We obtained a total of 20 clones producing agglutinating anti-B antibodies 
(Table 1), and for all clones we sequenced cDNAs coding for variable regions. The analysis revealed that all of 
the specific clones generated by immortalization of splenocytes derived from a single RBCs-immunized mouse 
produced exactly the same antibody (Table 2). Therefore, by immunizing three mice, we obtained three different 
antibodies, M18, O10 and Q6, that were specific to the B antigen of the ABO blood group system. We expected 
all of the antibodies obtained to be of IgM class because only IgM is considered capable of RBCs agglutination in 
saline16. Indeed, two of the antibodies, O10 and Q6, were IgM κ and IgM λ , respectively. Unexpectedly, the third 
antibody, M18, was of the IgG3 κ isotype. Moreover, this IgG3 antibody appeared affinity-matured, displaying a 
high number of amino acid substitutions when compared to the germline sequence. Figure 1 presents a complete 
sequence of M18 variable (V) region and its molecular model. Both the amino acid sequence and the structure do 
not diverge from a typical mouse IgG3 molecule. The cell culture medium containing the M18 antibody induced 
Fusiona Clones tested
Clones producing 
agglutinating mAbs Name of the specific antibody used in 
further experimentsnon-specific specific
M 2625 6 3 M18
O 1784 1 6 O10
Q, U 2854 14 11 Q6
Table 1.  Summary of fusions. aLetters denominate independent fusions; Q, U – splenocytes from one mouse 
were used for two fusions.
Fusion 
Genes coding for a variable fragment of the specific mAba 
(identity with the closest V-region)
Mutationsb HC/LC
Amino acid 
substitutionsc HC/LC IsotypeHeavy chain (HC) Light chain (LC)
M
IGHV1-9* 01 F (94%)  
IGHJ2* 01 F (94%)  
IGHD2-4* 01 F
IGKV1-99* 01 F (95%)  
IGKJ4* 01 F (100%) 16/6 12/3 IgG3 κ 
O
IGHV6-7* 02 F (96%)  
IGHJ4* 01 F (96%)  
IGHD1-1* 02 F
IGKV1-110* 01 F (96%) 
IGKJ1* 01 F (100%) 5/2 3/2 IgM κ 
Q, U
IGHV4-1* 02 F (97%)  
IGHJ3* 01 F (92%)  
IGHD5-8* 01
ndd 3/nd 0/nd IgM λ 
Table 2.  Analysis of specific antibody sequences. aSequence analysis revealed that all specific clones derived 
from a single mouse produce exactly the same mAb. bMutations with respect to the germline sequence were 
analysed within FR1-FR3. cAmino acid substitutions with respect to the germline sequence were analysed 
within FR1-FR3. dNot determined. Despite many efforts we did not manage to design λ -specific primers 
allowing for selective amplification of a productive assemblage of λ VJ-genes.
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a strong and rapid agglutination reaction, in contradiction with the agglutinating antibody paradigm. Thus, we 
decided to further investigate M18 and to compare its properties with IgMs that are currently used in serology.
IgG3-induced haemagglutination depends on the IgG3 constant region. As described above, we 
isolated an IgG3 capable of RBC agglutination. This ability may result from the structure of M18 V region, in 
which case it would be limited to this particular antibody, or from the structure of its constant region, in which 
case it would represent a general feature of the mouse IgG3 class. To investigate which part of the antibody was 
responsible for the agglutination property, we cloned the V regions of two agglutinating antibodies, M18 IgG3 
and O10 IgM, into commercial mouse IgG1 and IgG3 frameworks (Fig. 2a). All of the newly obtained antibody 
variants retained the ability of parental molecules to bind the antigen (Supplementary Figure 2). Media collected 
from cultures of HEK293 cells expressing the antibodies or saline solutions of purified immunoglobulins were 
gently mixed with a 0.45% (haematocrit) suspension of group B erythrocytes for 20 min. Agglutination was eval-
uated using a microscope. M18_IgG3 and O10_IgG3 agglutinated erythrocytes, whereas the IgG1 switch variants 
of these antibodies did not induce haemagglutination (Fig. 2b,c).
Agglutination triggered by O10_IgG3 was weaker than that by M18_IgG3. As the EC50 of M18_IgG3 binding 
to immobilized type B RBCs was significantly lower than that of O10_IgG3, this difference was likely due to dif-
ferences in the affinity of these antibodies towards the one-epitope B antigen (Fig. 2d). This effect is not surprising 
given that O10_IgG3 contained the variable fragment of the non-affinity-matured IgM, while M18 likely under-
went affinity maturation (Table 2).
Overall, these results suggest that the ability to induce haemagglutination is a general feature of mouse IgG3s 
that recognize antigens present on erythrocytes.
M18-induced agglutination is not dependent on the Fc fragment. Mouse IgG3 antibodies have an 
ability, exceptional among murine IgGs, to weakly interact through their Fc fragment and to form oligomers upon 
antigen binding6,9,19–21. To analyse whether the Fc fragment is crucial for the agglutinating capability of IgG3, we 
removed the Fc portion of M18 via pepsin digestion. The enzymatic cleavage resulted in a highly pure divalent 
Figure 1. Variable region (V region) of M18 antibody. (a) V region sequences of M18. (b,c) Model of M18 
V region complexed with its cognate antigen, blood group B trisaccharide (red). A molecular surface formed 
by CDRs is coloured using the same tints as in part a. The antigen was docked in a groove formed by the CDRs, 
where amino acid residues involved in the interaction with the antigen are most likely present. (c) Antigen in 
M18 binding site. The terminal galactose, unique for antigen B, is indicated.
www.nature.com/scientificreports/
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F(ab′ )2 fragment of M18 (Fig. 3a,b). The obtained M18 antibody F(ab′ )2 fragment retained the ability to agglu-
tinate RBCs (Fig. 3c), indicating that the agglutination capability of M18 does not depend on its Fc fragment.
Unique hinge region of IgG3 increases the span between antigen binding sites – in silico studies. 
As we excluded the role of the Fc fragment in the IgG3-induced agglutination, we focused on the F(ab′ )2 fragment 
of the M18 antibody. The heavy chain of M18-derived F(ab′ )2, which retains the ability to agglutinate, consists 
of the V region, the CH1 domain and a hinge region. We hypothesized that F(ab′ )2 contains a motif, unique to 
IgG3, that spans the antigen-binding sites. To investigate if IgG3 diverges from other mouse IgG subclasses in this 
respect, we performed multiple sequence alignment of M18 IgG3 and M18 modelled as IgG1, IgG2a and IgG2b 
isotype variants (Supplementary Figure 3). The analysis revealed that the major differences between mouse IgG 
subclasses are in the hinge region. IgG3 has an extraordinarily long upper hinge, which is bordered by the first 
hinge amino acid and a cysteine, forming the first inter-heavy chain disulphide bond22. To analyse how differences 
in the upper hinge lengths between mouse IgG subtypes influence the theoretical range of antigen binding sites, 
we generated models of M18 isotype variants using comparative molecular modelling. The models indicated that 
Figure 2. Haemagglutination induced by mouse IgG3. (a) The drawing schematically presents cloning of 
variable fragments into IgG3 and IgG1 frameworks. (b) IgG1 and IgG3 with the same variable fragments were 
compared in terms of their ability to agglutinate erythrocytes. Antibody concentration in the analysed cell 
culture media was determined using ELISA. Representative results of three independent experiments. Scale 
bar –100 μ m. (c) Since O10_IgG3 was less efficient in haemagglutination than M18, the experiment presented 
in b was repeated using higher concentration of purified O10_IgG3 and O10_IgG1 antibodies. Representative 
results of two independent experiments. Scale bar –200 μ m. (d) The EC50 of antibody binding to immobilized 
type B RBCs. Data points represent mean values obtained for triplicates of analysed samples. The experiment 
was performed two times. The EC50 of M18_IgG3 was approximately three times lower than the EC50 of O10_
IgG3 in both repetitions.
www.nature.com/scientificreports/
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the upper hinge of IgG3 is 1–2 nm longer than in other isotypes (Fig. 3d). Assuming that the Fab portion of an 
antibody has a constant size, the range of antigen binding sites should depend only on the upper hinge length. 
Based on two assumptions: (i) an immunoglobulin molecule has a planar conformation and (ii) the angle between 
the Fab fragments varies from 90° to 120°23, the in silico analysis indicates that the range of antigen binding sites 
in a divalent IgG3 molecule may be 2.8–3.4 nm longer than in other subtypes. This structural property likely 
explains the unique ability of IgG3 to agglutinate erythrocytes.
Figure 3. Structural determinants of mouse IgG3 agglutination capacity. (a–c) RBCs agglutination induced 
by F(ab′ )2 of M18 antibody. (a) Pepsin digestion removes the Fc fragment from the IgG molecule, resulting 
in F(ab′ )2. (b) Purity of M18 and its F(ab′ )2. An intact IgG antibody under reducing conditions migrates as 
two bands corresponding to heavy chain (HC, approximately 50 kDa) and light chain (LC, 25 kDa). HC’ is a 
heavy chain digested with pepsin. F(ab′ )2 is a protein with molecular mass of approximately 120 kDa, which 
was confirmed by the SDS-PAGE and western blotting under non-reducing conditions. Samples in western 
blotting were probed with anti-mouse-Ig antibody. IgG under non-reducing conditions migrates as two or 
three bands. A small amount of Fab is inevitably generated during pepsin digestion. (c) Haemagglutination of 
group B erythrocytes induced by mouse IgG3-derived F(ab′ )2, vehicle buffer, and intact parental M18 antibody. 
(b,c) are representative results of five independent experiments. (d) Molecular modelling of the hinge region in 
M18 isotype variants. For each isotype a distance between alpha carbon of the first hinge amino acid and alpha 
carbon of the first cysteine residue involved in the inter-heavy chain disulphide bond is indicated. The sequence 
of the upper hinge region is presented for each subtype in red. For the sake of clarity, only one heavy chain was 
presented. The models of M18 IgG1, IgG2a and IgG3 variants were generated with C-score greater than 0.9, 
which indicates high confidence of the predicted models. C-score calculated for the M18 IgG2b model was 
slightly lower and reached 0.5 due to a lack of a complete mouse IgG2b structure in PDB database that could be 
used as a template in the modelling algorithm.
www.nature.com/scientificreports/
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Comparison of IgG3 and IgM as diagnostics reagents. We next compared the usefulness of IgG3 and 
IgMs in blood typing. Hybridoma cells were seeded at a density of 5 × 104 cells/ml and cultured for 72 h. The anti-
body concentrations in media collected from the cultures and the corresponding antibody titres (as evaluated by 
slide agglutination; see Materials and Methods section: “RBCs and agglutination”) were as follows: 29 μ g/ml and 
64; 6 μ g/ml and 16; and 15 μ g/ml and 32 for clones producing M18 (IgG3), O10 (IgM) and Q6 (IgM), respectively. 
The specificity of the obtained antibodies was analysed using numerous freshly donated human blood samples 
of predetermined blood groups (Table 3). Each antibody was also tested in an indirect antiglobulin test and in 
agglutination of papain-treated RBCs. Negative results were consistently obtained when group A or group O 
blood samples were assayed. Importantly, M18, O10 and Q6 efficiently agglutinated RBCs from pregnant women 
and newborns (data not presented). Such RBCs may have reduced levels of ABO antigens18. To obtain antibody 
preparations with titres comparable to those of commercially available blood grouping reagents, we produced the 
antibodies using disposable bioreactors. The media collected from the cultures in bioreactors after cell separation 
and supplementation with buffers and preserving agents gave high-quality diagnostic reagents, which induced 
agglutination within 5–10 s and reached agglutination scores as high as 4+ within 1 min of contact between the 
reagent and a blood sample. Slide agglutination titres of M18-, O10- and Q6-based reagents were 256, 512 and 
128, respectively.
We also compared the agglutination capacity of IgG3 and IgMs (Table 4). Three nanomolar solutions of M18, 
O10 and Q6 antibodies in saline were serially diluted and mixed with a 0.45% (haematocrit) suspension of RBCs. 
After 20 min of incubation, the results were evaluated using a phase-contrast microscope. We assumed that the 
IgMs were pentamers with a molecular mass of approximately 970 kDa. This assumption was made because: (i) 
the expression of J chain favours the secretion of pentameric IgMs24; and (ii) the analysed hybridomas, as well 
as Sp2/0 myeloma (fusion partner), expressed J chain (Supplementary Figure 4). With respect to IgG3 and IgM 
agglutination capacities, agglutination scores of 1+ were observed in the presence of 4–7 times more M18 mole-
cules than for the two analysed IgMs (Table 4). The molecular mass of IgGs is approximately 6 times smaller than 
that of IgMs; thus similar amounts (in mass) of specific IgG3 and IgM are required to elicit the same degree of 
agglutination.
To verify whether the IgG3-based reagent may be more profitable than IgM-based reagents, we determined 
the productivity and doubling times of the clones that produced M18, O10 and Q6 antibodies. IgG3 was pro-
duced approximately three times more efficiently than IgMs (Supplementary Figure 5). The three analysed cell 
lines exhibited similar doubling times (Supplementary Figure 5); thus the overall antibody yields depend primar-
ily on cell line productivity.
Stability of IgG3- and IgM-based reagents. Monoclonal reagents used in serology, rather than being 
purified antibodies, are usually filtered and buffered media collected after fed-batch bioprocess. The reagents 
are often supplemented with preservatives and agents that enhance agglutination. To compare the stability of 
IgG3- and IgM-based reagents, we prepared simple formulations of M18, O10 and Q6 antibodies by buffering 
the culture media with 20 mM Tris-HCl pH 7.5 and adding 0.01% thiomersal. To accelerate any possible changes 
blood 
group
M18 O10 Q6
donations
positive 
results donations
positive 
results donations
positive 
results
0 20 — 20 — 13 —
A1 17 — 5 — 8 —
A2 13 — 5 — 3 —
A1B 17 17 2 2 3 3
A2B 6 6 2 2 — —
B 52 52 30 30 13 13
Table 3.  Specificity of M18, O10 and Q6 antibody evaluated using agglutination of fresh blood samples.
concentration [nM]
O10 (IgM) samples Q6 (IgM) samples M18 (IgG3) samples
Ia II III I II III I II III
3.00 2+ 2+ 2+ 3+ 3+ 3+ 1+ 2+ 2+ 
1.50 2+ 2+ 1+ 2+ 2+ 3+ + /− 1+ 1+ 
0.75 1+ 1+ + /− 1+ 1+ 1+ — — —
0.38 1+ + /− + /− 1+ 1+ 1+ — — —
0.19 + /− + /− + /− 1+ 1+ 1+ — — —
0.09 — — — + /− + /− + /− — — —
0.05 — — — + /− — — — — —
0 — — — — — — — — —
Table 4.  Comparison of IgM and IgG3 agglutination capacity. aPresented results are from three independent 
experiments designated as I, II and III.
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in their activity that may occur during storage, we used the classical procedure of keeping the formulations at 
42 °C for 7 days25,26. The samples’ activities were tested daily via slide agglutination assays (Table 5). IgM anti-
bodies lost their ability to agglutinate more rapidly than did IgG3. IgMs began to lose their functionality after 
24–48 h at 42 °C. In contrast, IgG3 M18 was stable for at least 5 days at 42 °C. The results were consistent with 
our previous observation that IgMs, but not IgG3, relatively quickly lose their activity even when stored at room 
temperature. Moreover, O10 and Q6 could not be frozen and thawed without losing activity, in contrast to M18, 
which retained full activity even after 10 cycles of freeze-thawing (data not presented). Although the low stability 
of IgM is well known27,28, the molecular mechanisms responsible for the rapid loss of its activity remain unclear. 
Thus, we investigated the molecular basis of IgM instability. First, we used western blotting to analyse the samples 
that were collected during the accelerated storage study. As presented in Fig. 4a, during storage at 42 °C, (i) the 
μ heavy chain underwent truncation in the IgM-based reagents, resulting in a μ ′ chain with a molecular mass of 
approximately 55 kDa; and (ii) non-reducible aggregates were formed in the IgM-based reagents. Both changes 
increased with time. To determine if the formation of truncated μ ′ chain is a direct chemical or enzyme-mediated 
process, we incubated samples of five different IgMs, formulated as described above, with a protease inhibitor 
cocktail (Fig. 4b). The inhibitors prevented the increase in the levels of μ ′ chains but promoted the formation of 
both reducible and non-reducible aggregates (Fig. 4b, lower panel). We next asked whether the proteases involved 
in μ chain trimming originated from hybridoma cells themselves or derived from the FBS. The latter was the case. 
Specifically, purified IgMs remained intact during storage at 4 °C or 42 °C but were trimmed in the presence of 
FBS (Fig. 4c). The truncation was even more pronounced when FBS was replaced with an equivalent amount of 
serum bovine albumin, which was obtained by heat treatment (ht-BSA). Although the reagent is supposed to 
contain primarily albumin, it is also enriched in numerous other proteins, as demonstrated in Supplementary 
Figure 6. The protease of interest most likely co-precipitates with albumin during the fractionation of the serum. 
The observed significant increase in IgM proteolysis upon replacement of FBS by BSA may also result from 
the removal of major plasma proteinase inhibitors, such as α -1-antiproteinase and α -2-macroglobulin during 
FBS fractionation. We also analysed whether the truncation of μ chain occurs in mouse serum. We observed an 
increase in μ ′ chain levels after incubation of mouse serum samples at 42 °C for 4 days (Fig. 4e). This result indi-
cates that the protease that trims the μ chain is present not only in bovine serum but also in species-compatible 
mouse serum and suggests that this mechanism of IgM instability is likely to occur in vivo.
To further characterize the differences in the stability of IgG3 (M18) and IgMs (O10 – home-made and MM30 – 
commercial) and to examine whether the storage of the formulations affects the stability of the immunoglobulins, 
we performed differential scanning calorimetric (DSC) analyses. DSC measures the enthalpy of protein unfolding 
that results from thermal denaturation. For small, one-domain proteins, thermograms that show a dependence 
of molar heat capacity of denaturation (cp) on temperature usually consist of a single heat absorption peak. The 
maximum of this peak, denoted Tm, is the thermal transition midpoint and defined as the temperature where 
50% of the protein is in its native conformation and the rest is denatured. The higher the Tm, the more stable the 
protein. However, for multidomain proteins, such as immunoglobulins, the thermograms reflect a multi-state 
denaturation process and are more complex. This complexity originates from the merging of overlapping peaks 
that represent the thermal transitions of individual domains. The area under the curve, i.e., the integral of the 
molar heat capacity, equals the calorimetric enthalpy change (Δ Hcal), which reflects the energy required for total 
protein unfolding.
Samples of the antibodies that were stored for 5 days at 4 °C (control) or 42 °C were subjected to DSC analy-
ses (Fig. 5a). For each antibody, scans of control and heated samples resulted in the thermograms with a similar 
overall shape and Δ Hcal. The maxima (Tm) of the fitted two-state scaled transitions were the same for control and 
heated samples but differed for each antibody. The thermogram of M18 was deconvoluted into three overlapping 
peaks, which most likely corresponded to the CH2 (Tm1 = 62.5 °C), CH3 (Tm2 = 71 °C) and Fab (Tm3 = 74.5 °C) 
transitions29. In the case of O10, the thermogram consisted of two transitions with Tm1 = 66 °C and Tm2 = 73.5 °C. 
The contributions of the first and second transition to total Δ Hcal observed for the control, non-heated O10, 
were 59% and 41%, respectively. The Fab fragments account for approximately 57% of the pentameric IgM mass 
(excluding N-glycans), whereas the remaining 43% is the mass of the Fc fragment. A consistency between the 
Fab:Fc mass proportion in a complete IgM and the relative contribution of the separate transitions in the O10 
Time [days]
O10 (IgM) Q6 (IgM) M18 (IgG3)
duplicates duplicates duplicates
I II I II I II
0 16a,b 32 32 32 32 32
1 16 16 16 16 32 32
2 16 8 4 8 32 32
3 8 8 — 2 32 32
4 8 8 — 2 32 32
5 8 8 — 2 32 32
6 4 8 — — 16 32
7 2 4 — — 16 16
Table 5.  Stability of IgM and IgG3 antibodies at 42 °C. aAgglutination-inducing titres of the antibodies after 
indicated time of heating. bRepresentative results of three independent experiments performed in duplicates are 
shown.
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Figure 4. Chemical instability of IgM – western blotting analyses. All samples were probed with HRP-
labelled anti-mouse IgM κ polyclonal antibodies. (a) O10- and Q6-based reagents were incubated at 42 °C 
for 6 days. Amount of truncated heavy chain (μ ′ ) increased in subsequent samples taken daily. Images are 
representative of four independent experiments. (b) Protease inhibitor cocktail prevented trimming of a 
heavy chain, but promoted the formation of both reducible and non-reducible disulphide-based aggregates. 
Amount of IgM aggregates with the high molecular mass increased after exposure to elevated temperature. 
Representative results of four independent experiments are shown. Blots in (b) present the same samples 
www.nature.com/scientificreports/
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thermogram suggest that Fab domain unfolding precedes Fc fragment unfolding in this molecule. Although in 
the case of heated O10 the measured Δ Hcal was similar to the control samples, we observed a shift in the relative 
contributions of separate transitions (Fig. 5b). Scans of the MM30 samples showed broad thermograms, with at 
least three overlapping transitions. O10 and MM30 are both of the IgM class, but the analysed MM30 samples 
contained many more truncated heavy chains than the O10 preparations (Fig. 5c). We calculated the Fab:Fc mass 
proportion for MM30, taking into consideration the quantity of the truncated heavy chain. A direct comparison 
between the proportion and a contribution of the fits to Δ Hcal did not allow us to determine which transitions 
correspond to particular domains of the MM30 antibody.
In summary, the DSC analyses indicated that the stability of the M18 IgG3 Fab fragment is higher than that 
of O10 IgM. However, storage of either antibody for 5 days at 42 °C does not lead to evident structural changes 
that might be reflected by DSC profiles. Small changes in DSC profiles were observed for O10 IgM but not for 
M18 IgG3.
Mouse immunization with RBCs leads to increased serum levels of IgM and IgG3. To assess 
whether the mouse that was the splenocyte donor for the fusion that generated M18 had an exceptionally high 
IgG3 serum level, we compared concentrations of IgM and IgG3 in this mouse and in several other immunized 
and non-immunized mice (Fig. 6). As expected, all of the immunized mice had increased both IgM and IgG3 
levels compared to controls; however, the serum levels of particular isotypes did not correlate with the isotype of 
the specific agglutinating antibody that was obtained (Table 2). Therefore, the generation of agglutinating IgG3 
cannot be predicted on the basis of IgG3 and IgM concentration in the serum.
Discussion
Mouse IgG3 has a unique hinge region, which may underlie its agglutination capability. 
Atypical properties of mouse IgG3 have been reported since its discovery in 19718. Among mouse IgGs, only IgG3 
can interact (albeit weakly) via their Fc fragments. Although the estimated binding constant of the Fc-dependent 
interaction between mouse IgG3 molecules is low9, this self-association seems to have a tremendous impact on 
their properties7,14,20. The significance of the Fc fragment in mediating IgG3’s unique characteristics prompted 
us to determine whether this fragment is also responsible for the observed agglutination capability of IgG3. 
Unexpectedly, divalent F(ab′ )2 prepared by pepsin-digestion of M18 retained agglutination capability, clearly 
indicating that M18-induced haemagglutination does not depend on the Fc fragment. We also prepared recombi-
nant IgG1 and IgG3 isotype variants of two agglutinating antibodies, M18 (IgG3) and O10 (IgM). We showed that 
IgG3s with variable regions derived from M18 or O10 retained the ability to agglutinate RBCs, while correspond-
ing IgG1 molecules did not induce direct haemagglutination. The results indicate that the ability to cross-link 
erythrocytes is a general feature of mouse IgG3, but not IgG1. To determine the molecular mechanism behind 
IgG3-triggered haemagglutination, we focused on the upper hinge of the antibody. This region determines the 
flexibility of an IgG molecule and indirectly influences its effector functions22. The upper hinge in mouse IgG3 is 
the longest of all mouse, rabbit and human IgG upper hinges. Moreover, the hinge region of mouse IgG3 is rigid, 
in contrast to the flexible hinges of other IgGs22.
In silico analysis was performed on model M18 isotype variants and indicated that the range of Fabs in IgG3 
may be up to 3.4 nm longer than in other isotypes. However, the actual differences in the range of the Fab arms of 
different IgG subtypes are difficult to determine. Previously published reports concerning Fab ranges in mouse 
and human IgGs showed that the distance between Fabs depends on the antibody molecule geometry and its flex-
ibility17,23. On the other hand, Sosnick et al. demonstrated that a functional Fab range does not directly correlate 
with the upper hinge length, e.g., mouse IgG1 and IgG2b have similar range of Fab arms, approximately 134 Å17, 
although the upper hinge of IgG2b is five amino acids longer than that of IgG1.
Comparative molecular modelling, which we applied in our work, does not provide a direct insight into the 
molecule dynamics but allows accurate measurements of theoretical distances between atoms. The in silico results 
suggest that mouse IgG3 has a uniquely extended span of Fab arms. We hypothesize that this feature of IgG3 
accounts for its agglutination capability, and this hypothesis is supported by two experimental observations. First, 
all A- or B-specific antibodies that have been reported as suitable for serological diagnostics are of the large-span 
IgM class30–32; second, A- or B antigen-specific IgGs of an isotype other than IgG3 cannot agglutinate RBCs33,34. 
In summary, mouse IgG3 considerably differs from other IgG subtypes, especially in the extended length of the 
upper hinge. This characteristic may result in an unusually large range of its Fab arms and allow for the aggluti-
nation of RBCs.
resolved under reducing and non-reducing conditions. HC – heavy chain, LC – light chain. (c) Protease(s) 
present in serum trim(s) the IgM heavy chain. Purified IgM antibodies were incubated with 5% FBS or ht-BSA 
(1.5 mg/ml) for 4 days at indicated temperatures. The bar chart presents relative amounts of truncated heavy 
chain quantified using densitometry. The intensity of a band corresponding to the μ ′ chain in the control sample 
without additive incubated at 4 °C was defined as 1. The μ′ chain in samples with additives migrates slightly 
faster than in control, probably due to the presence of the large band of serum albumin, which molecular mass is 
approximately 66 kDa. The chart presents mean values derived from two separate blots prepared from the same 
samples in one experiment. Results in (c) are representative of two independent experiments. (d) Truncation of 
μ chain occurs in mouse serum. Samples of mouse serum were incubated in parallel at 4 and 42 °C for 4 days. 
The figure presents a result obtained for one serum sample representative of three out of four analysed samples 
collected from different mice (in one sample the levels of μ ′ were similar at 4 °C and 42 °C).
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Figure 5. DSC analyses. (a) DSC thermograms of M18, O10 and MM30 samples stored at 4 °C as well as 
heated at 42 °C for 5 days. Black solid lines represent experimental data, which then were fitted with the two-
state scaled model provided by TA Instruments (grey dashed lines). Dotted lines are sums of the fits. Maxima 
of the fits (Tm) are indicated. Obtained Tm values were the same for both control and heated samples of the 
antibodies. (b) Contribution of the two separated transitions of O10 antibody to total Δ Hcal. The chart presents 
mean values from two independent experiments. (c) SDS-PAGE of MM30 and O10 samples analysed with DSC. 
Proportion of truncated to full length heavy chain in MM30 samples was approximately 1:3 (densitometric 
analysis). The truncated heavy chain was almost undetectable in O10 samples.
www.nature.com/scientificreports/
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Proteolytic truncation of IgM heavy chain occurs extracellularly and depends on serum proteases. 
The co-expression of two IgM heavy chain isoforms, full-length (μ ) and truncated (μ ′ ), was observed several years 
ago35,36. The isoforms were detected in both human and mouse serum, as well as in supernatants from cell lines 
derived from these species. The truncated chain lacks a variable domain35,36. Previous studies have shown that the two 
isoforms are produced by translation of alternatively spliced transcripts of a single μ chain gene35. Here, we demon-
strate that the μ ′ chain can also be produced by proteolytic trimming of a full-length heavy chain. Thus, we provide 
evidence that IgMs may be subjected to posttranslational proteolytic processing that occurs extracellularly and is 
catalysed by an unidentified serum protease(s). We showed that these enzymes are present both in mouse and bovine 
serum. We are currently investigating the specificity of this putative enzyme(s), which may facilitate its identification.
Our findings have several important implications. IgMs are produced early during the adaptive immune 
response and can induce strong cytotoxic effects after binding to a cell-associated antigen. According to our 
results, a protease present in mouse serum cleaves off a variable fragment of the IgM heavy chain. The loss of this 
variable domains leads to reduced avidity and to the generation of trimmed molecules, the physiological roles of 
which are undetermined.
There are three Ig receptors that can bind IgMs: one that is exclusively IgM-specific (Fcμ R)37 and two that are 
IgM- and IgA-specific (pIgR and Fcα /μ R)38. IgM binding to these receptors is independent of the antibody variable 
fragment37,39; thus, we speculate the following: (i) IgM transport across the epithelium should not be impaired by the 
truncated heavy chain, but trimmed molecules may provide inefficient immune protection; (ii) uptake of IgM-coated 
antigens by follicular dendritic cells and B-cells expressing Fcα /μ R38 might be blocked by truncated IgMs; and (iii) 
the functions of Fcμ R-expressing B- and T-cells, as well as NK lymphocytes38,40, may also be modified by the trimmed 
IgM variants. Moreover, truncated IgMs likely have a reduced ability to activate complement. Our results suggest that 
the physiological functions of IgMs may be attenuated due to N-terminal trimming by serum proteases.
IgM aggregation and μ heavy chain truncation lead to a rapid decrease in IgM activity. Research 
in the field of immunoglobulin structure, stability and formulation has been carried out for many years, and a 
vast amount of information concerning IgGs is available in the literature [reviewed by Wang et al.26]. In contrast 
to IgGs, factors and processes that influence the stability of IgMs are much less understood. Studies on IgM 
stability and formulations are important to pharmaceutical science because, due to their potent complement 
activation capabilities, IgMs are among the candidates for next generation antibody therapeutics41. In comparison 
to IgGs, IgMs are much less stable, and their production is demanding and inefficient27,41. Although the sensitiv-
ity of IgMs to elevated temperature and freezing is widely known, the exact molecular mechanism behind IgM 
Figure 6. Serum IgG3 and IgM concentrations in RBCs-immunized mice. Samples of mouse serum 
were assayed using IgG3- and IgM-specific ELISAs. Samples from 11 different mice at age 25–29 weeks were 
analysed, among which 5 animals were immunized with RBCs. Arrows indicate serum sample of mouse no. 5, 
whose splenocytes were used in fusion resulting in M18 antibody generation. Agglutination was assessed for 
samples diluted 100 times. Error bars correspond to SD of concentration measurements.
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instability is still not understood. In the present work, we used the accelerated storage test to investigate changes 
in the activity of IgM-based monoclonal reagents for blood typing. The analysed IgMs rapidly lost agglutination 
capability at 42 °C, an effect that was correlated with their aggregation and trimming of their heavy chains. Our 
results indicate that the observed aggregation is a dominant process that causes the loss of activity. According to 
western blotting analyses performed on samples that were resolved under reducing and non-reducing conditions, 
the aggregation seems to be primarily disulphide-based. However, significant levels of non-reducible aggregates 
were observed in IgM samples that were stored at 42 °C. The formation and exchange of disulphide bonds is the 
most common pathway that leads to IgG aggregation during storage26. We also report a specific and proteolytic 
trimming of the IgM heavy chain. The observed truncation occurred extracellularly and increased with time. We 
cannot determine how important the heavy chain truncation is for the IgM stability based on these results. We 
would like to emphasize that the activity of IgM-based reagents after 6 days of storage at 42 °C was significantly 
reduced or almost completely lost, despite there being a large amount of full-length heavy chain in the reagent. 
The attempts to prevent the trimming using protease inhibitors unexpectedly resulted in the promotion of aggre-
gate formation, an effect that was likely induced by one or several active components of the inhibitor cocktail. 
Moreover, we hypothesize that the inhibition of heavy chain trimming itself may induce IgM aggregation by a 
currently unknown mechanism. One group has reported a decrease in the molecular mass of two mouse IgMs 
(from approximately 950 kDa to approximately 600–800 kDa) during storage in PBS over 180 days at 37 °C; this 
effect was accompanied by progressing aggregation. The aggregation and fragmentation were both clearly inhib-
ited by lowering the pH to 5.5 and the addition of 20% sorbitol28. When all heavy chains in a pentameric IgM mol-
ecule were trimmed to 55 kDa polypeptides, the molecular mass of the whole oligomer decreased from 970 kDa 
to approximately 800 kDa, which is in the mass range reported in the cited work. Thus, it seems possible that the 
authors observed the heavy chain trimming catalysed by residual serum proteases. This trimming seems to be 
an initial step of IgM fragmentation and is followed by further proteolysis events, the loss of the light chain, and 
deglycosylation, resulting in a lowering of the IgM molecular mass to 600 kDa.
DSC analyses revealed that the Fab of M18 (IgG3) has a high Tm, falling between 70 °C and 80 °C, which is the 
range for IgGs reported by other investigators42. The DSC thermogram of O10 (IgM) consisted of two transitions, 
the first of which likely originates from the Fab. Mueller et al.28 presented thermograms of eight different IgMs 
and, similar to our data, the highest peak (Tm between 63–68 °C at pH 7.5) appeared at the beginning of the ther-
mal unfolding for each IgM28.
Comparison of the thermograms for IgGs and IgMs indicates that the denaturation of the Fab in IgM occurs 
at a lower temperature than for IgG. This effect may reflect differences in the stability of IgGs and IgMs that are 
stored at elevated temperatures. An unfolding event occurring at the lowest temperature during DSC scan is often 
considered as an indicator of the overall protein stability43. The first peak observed in IgG thermograms reflects 
the CH2 domain29. Although the CH2 unfolding has a lower Tm than the putative transition of the IgM Fab, it is 
reversible; thus, it should not affect the overall stability of the IgG42.
The influence of heating at 42 °C was noticeable in the case of O10 samples that were subjected to DSC exper-
iments. The total Δ Hcal did not change after pre-treatment of O10 at elevated temperature. This result indicates 
that none of the domains of O10 stored at 42 °C for five days underwent significant unfolding. However, ther-
mograms obtained for the control and preheated O10 samples differed in the relative contribution of to the total 
Δ Hcal. We believe that this change reflects slight structural and/or chemical alterations that occurred during the 
accelerated storage of O10. The results that were obtained for MM30 suggest that the truncated heavy chain may 
influence the thermal unfolding of IgM, thus affecting the stability of the antibody during storage. To test this 
hypothesis, mutated IgMs that are resistant to truncation should be generated and their DSC profiles compared 
with those of parental proteins.
Mouse IgG3s could replace IgMs in haemagglutination assays. Mouse IgG3s may be more feasible 
and interesting alternatives to IgMs, which are currently used in the serological determination of blood groups. 
IgMs have two major drawbacks in that (i) they are unstable, sensitive to heat and freezing; and (ii) their produc-
tion and purification is usually inefficient and demanding27,41. As we have demonstrated, M18 IgG3 has an agglu-
tination potential similar to IgMs but is advantageously durable and efficiently produced. Agglutinating IgG3s 
seem to be extremely rare. We were able to find only three reports of such antibodies. One of these, 2H12, rec-
ognizes glycophorin A44. In this case, the ability of IgG3 to agglutinate did not cause much surprise because gly-
cophorin A protrudes significantly from the erythrocyte glycocalyx; thus, the distance between two epitopes on 
two cells is much smaller than the distance between cell surfaces. Another example is IgG3 clone 6.1.5, reported 
in 198434 which is capable of the agglutination of both A- and B-group RBCs. However, this discovery was not 
translated into a diagnostic application due to broad specificity of the antibody. The third report, by Blanchard 
et al.45, concerned three IgG3s: NaM-1C9 (anti-A), NaM-1F6 (anti-A) and NaM-2E11 (anti-B). These IgG3s 
showed low haemagglutination potential, making them suitable for flow cytometry analysis of RBCs45.
In contrast to the previously reported IgG3 antibodies with similar specificity, M18 is an absolutely specific 
IgG3 antibody that exhibits a haemagglutination potential similar to IgMs. Thus, M18 may be used in routine 
blood typing based on direct haemagglutination testing.
On the basis of our results, we hypothesise that the ability of mouse IgG3 to agglutinate is an intrinsic trait 
of this molecule that results from its unique structure and does not depend on epitope localization. Although 
detailed studies on M18 structure-function relationship may provide a deeper insight into mouse IgG3 biochem-
istry, the validity of this hypothesis is still an open question. The generation of a genetically engineered mouse 
IgG3s with variable domains that are derived from an antibody that recognizes antigen D from the Rh blood 
group system could provide the answer. As the D antigen is localized very close to RBC plasma membrane46, 
obtaining anti-D agglutinating IgG3 would provide ideal evidence for our hypothesis that mouse IgG3s could 
replace all fragile IgMs in direct agglutination assays.
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Overall, the M18 agglutinating antibody formulations compared favourably with IgM-based reagents and, 
given its major advantages in terms of stability and productivity, this antibody appears well suited for diagnostic 
applications.
Materials and Methods
RBCs and agglutination. Preserved standard human RBCs and samples of freshly donated blood were kind 
gifts from the Regional Centre of Blood Donation and Blood Treatment in Katowice, Poland. All of the blood 
samples tested negative for viral and bacterial pathogens. Agglutination tests, including indirect agglutination 
tests, were performed using the slide or tube technique according to the current World Health Organization 
guidelines16, unless otherwise stated. Agglutination was evaluated using a six-point scale, ranging from 4+ , 
reflecting complete agglutination, through 3+ , 2+ , 1+ , + /− and a negative score. The score ‘1+ ’ corresponds to 
weakly positive agglutination visible with the naked eye. Antibody titration was performed using a direct agglu-
tination test with serial two-fold dilutions of the antibody preparation. The titre was the highest dilution that 
induced a 1+ agglutination score.
Mouse immunization and hybridoma generation. Nine-week-old Balb/c mice, obtained from the 
Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, were immunized intraperitoneally 
with 2 × 107 washed RBCs suspended in 150 μ l of PBS. The cells were injected monthly, and at least 4 injec-
tions were given. Three days, two days and one day before the fusion, the mice were given a booster of an addi-
tional injection of RBCs. The hybridomas were generated using the protocol by Page and Thorpe47. The mouse 
myeloma cell line Sp2/0 was used as a fusion partner. Media collected from the wells with growing hybridoma 
clones were screened for antibody production using the slide agglutination test. The cells that produced antibod-
ies that specifically and exclusively recognized antigen B from the ABO blood group system were propagated 
and further subcloned using the limited dilution technique to ensure monoclonality. All of the animal experi-
ments were conducted in accordance with the standard guidelines by the National Ethics Committee on Animal 
Experimentation. The guidelines met the ethical standards required by Polish law (Animal Research Act, 2005) 
and by the European Directive 2010/63/EU on the protection of animals used for scientific purposes. All proce-
dures involving mice were approved by the Animal Experiments I Local Ethics Committee, Kraków (Approval 
No. 71/2009) and all efforts were made to minimize animal suffering.
Cell cultures and bioreactors. Hybridoma and HEK293 cells were cultured in DMEM with 4.5 g/l glucose 
(Lonza) and 5% FBS (Biowest) at 37 °C, 5% CO2 in a humidified incubator. To produce a formulation of antibod-
ies at a high titre suitable for diagnostics, the hybridoma cells were adapted to BD Cell Mab Medium Quantum 
Yield medium (BD Bioscience) and cultured in two-compartment disposable CELLine1000 bioreactors (BD 
Bioscience). All of the cell cultures were routinely screened for Mycoplasma spp. contamination using PCR with 
rDNA-specific GPO1 and MGSO primers48.
Analysis of nucleotide sequences of V regions. Genes encoding variable regions of antibodies were 
amplified as described by Wang et al.49 and sequenced using the dideoxy-chain termination technique (Genomed, 
Poland). The obtained sequences were analysed using the IMGT/V-QUEST program, version 3.3.5, provided by 
the International Immunogenetics Information System50,51.
Isotype switching. cDNAs encoding the V fragments of the heavy and light chains were inserted into pFU-
SEss plasmids containing sequences that coded for the constant region of mouse γ 1, γ 3 or κ chain (Invivogen). The 
V fragment of a heavy chain was cloned into pFUSEss-CHIg-mG1 and pFUSEss-CHIg-mG3 vectors using EcoRI 
and AfeI restriction sites. Similarly, the V fragment of a light chain was inserted into pFUSE2ss-CLIg-mK plasmid 
using EcoRI and BstAPI. All of the generated constructs were verified by sequencing (Genomed, Poland). The 
isotype variants were transiently expressed in HEK293 cells transfected using Lipofectamine 2000 (Invitrogen).
Comparative molecular modelling. Comparative molecular modelling of immunoglobulins was per-
formed on the I-TASSER server52 according to the protocol provided by the authors53. Models with the highest 
C-score, which indicates a high confidence of predicted models, were visualized and analysed using the PyMOL 
Molecular Graphics System, Version 1.3 (Schrödinger).
Antigen docking. The M18 antibody structure obtained using comparative molecular modelling was simu-
lated in GROMACS 4.6.554,55 for 10 ns with a CHARMM36 force field under conditions similar to those published 
by Rahimi et al.56. The structure of the antigen, the blood group B trisaccharide, was obtained from PubChem, 
molecule ID: 10206531, and parametrized for CHARMM36 using CGenFF 3.01 automated topology builder57,58. 
Then, B trisaccharide was docked in the M18 model using Autodock Vina59. The structure of the antibody com-
plexed with the docked antigen with the lowest binding energy was further simulated for 500 ps using the same 
parameters as before. Movement within the system was limited by a harmonic force of 10000 kJ × mol−1 × nm−1 
between the protein and B trisaccharide, and position restraints were put on carbon atoms in the fucose ring.
Antibody purification. CaptureSelect LC-kappa (mur) Affinity Matrix and CaptureSelect IgM Affinity 
Matrix (both from Thermo Fisher Scientific) were used for the purification of mouse monoclonal IgG3 and IgM 
antibodies, respectively. The purifications were performed according to the manufacturer’s instruction and were 
followed by dialysis against a buffer suitable for further procedures. The purity of antibodies was evaluated by 
SDS-PAGE and silver staining of the gels. The antibody concentration was determined using a BCA assay60, with 
bovine γ -globulin fraction (Pierce) as a reference.
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Fragmentation of IgG3 to F(ab′)2. Pepsin digestion of mouse IgG3 was performed essentially as described 
by Andrew61. The digestion time was experimentally optimized to 30 min. To separate F(ab′ )2 fragments from 
residual full-length antibodies, the reaction mixture dialyzed against PBS pH 8.0 was loaded onto protein A chro-
matography column (Pierce), and the unbound fraction containing F(ab′ )2, was collected.
ELISA. A standard sandwich ELISA62 was used for measurements of antibody concentration. Mouse IgM B 
Cell ELISpot Development Module (R&D Systems) and a standard of mouse IgM (clone MM30, Abcam) were 
used for the quantification of IgMs. The concentration of IgG3 in mouse sera was determined using goat poly-
clonal capture antibody specific towards mouse IgG3 (Sigma) and a biotinylated goat anti-mouse kappa poly-
clonal detection antibody (AbD Serotec). Bound biotinylated antibodies were detected with HRP-conjugated 
streptavidin (R&D Systems). The concentrations of IgG3 and IgG1 in cell culture media after transient expression 
were evaluated using a goat polyclonal capture antibody that recognizes the mouse kappa chain (AbD Serotec), 
a rabbit monoclonal anti-mouse IgG1/IgG3 detection antibody (clone M111-2, Abcam), and a HRP-conjugated 
goat anti-rabbit polyclonal antibody. Purified mouse IgG3 (clone M18) and IgG1 (clone MCP21, Sigma) were 
used as standards. A colorimetric substrate for HRP OptEIA (BD Bioscience) was used in all experiments. The 
absorbance was read with a Molecular Devices Versa Max (Sunnyvale, USA) microplate spectrophotometer, and 
the concentrations were calculated using SoftMax Pro software.
EC50 calculation. The EC50 was determined using ELISA on B-type RBCs, which were immobilized on the 
ELISA plates as described by Bigbee et al.63. Endogenous RBC peroxidase was blocked with 3% H2O2 for 20 min. 
The immobilized RBCs were incubated for 2 h with two-fold serial dilutions of HEK293 culture media contain-
ing transiently expressed M18_IgG3 and O10_IgG3 antibodies. The antibody concentrations in the media were 
determined using an IgG3-specific ELISA. The amounts of antibodies bound to RBCs were detected with biotiny-
lated goat anti-mouse kappa polyclonal antibodies (1:3000, AbD Serotec), HRP-conjugated streptavidin (1:40000, 
Sigma) and a colorimetric substrate for HRP OptEIA (BD Bioscience). The obtained absorbance values were 
plotted against concentrations of the antibodies using an on-line tool (www.ic50.tk), which was also used for the 
EC50 calculations.
Accelerated storage studies. Purified antibodies in PBS or filtered cell culture media adjusted to pH 7.5 
with 20 mM Tris-HCl were supplemented with 0.01% thiomersal (Sigma), a preservative commonly used for 
antibody formulations. M18, O10 and Q6 antibodies were in-house purified as described above. MM30 was 
purchased from Abcam. The media collected from cultures of O10, Q6, A19, A2 and 2E11 clones were used in 
the experiments. The in-house generated clones A19 and A2 produce IgMs that specifically agglutinate RBCs of 
blood group A, while the in-house generated clone 2E11 produces IgM specific towards a microbial antigen. The 
samples were stored at 42 °C and 4 °C for the indicated time periods. In some experiments, protease inhibitor 
cocktails (Sigma and Thermo Fisher Scientific) and 5 mM phenantroline (Bioshop) or appropriate volumes of 
their solvents (DMSO and methanol) were added to the culture medium. After the storage experiments, the sam-
ples were analysed using DSC or SDS-PAGE followed by western blotting.
SDS-PAGE and western blotting. SDS-PAGE performed according to the standard protocol64 in 10% or 
6% gels for reducing and non-reducing conditions, respectively. Protein separation was followed by a wet electro-
transfer onto a PVDF membrane (Millipore)65. After blocking with 3% skim milk in PBS for 2 h, the membrane 
was incubated for 1 h with goat polyclonal HRP-labelled anti-mouse IgM kappa (AbD Serotec) or goat polyclonal 
HRP-labelled anti-mouse-Ig (BD Pharmingen) detection antibodies. The bands were visualized using Immobilon 
Western Chemiluminescent substrate for HRP (Merck Millipore) and analysed with a Fusion Fx apparatus with 
the Fusion Capt Advance Fx5 program (Vilbert Lourmat, France).
Differential scanning calorimetry (DSC). The DSC experiments were performed using NANO DSC 
Series III System with Platinum Capillary Cell (TA Instruments), with an active volume of 0.3 ml. To avoid bub-
ble formation during heating mode, the samples were degassed prior to being loaded by pulling a vacuum of 
30.4–50.7 kPa on the solution for a period of 10–15 min. The sample cell was then filled with 0.3 ml of sample 
solution, and an equal volume of buffer was used as a reference. The cells were sealed and thermally equilibrated 
for approximately 10 min at the starting temperature. All of the measurements were performed on samples under 
0.304 MPa pressure. The data were collected in the range of 5–95 °C at a heating scan rate of 1 °C−1. Thermograms 
were corrected by subtraction of buffer blank scans and normalized to the protein concentration. Each data set 
was analysed for thermodynamic parameters with a software package supplied by TA Instruments. High values of 
the scaling factor (Aw) were allowed in the fitting algorithm.
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Mouse Antibody of IgM Class is 
Prone to Non-Enzymatic Cleavage 
between CH1 and CH2 Domains
Tomasz Klaus1,2, Krystyna Stalińska2, Dominik Czaplicki  2, Paweł Mak3, Bozena Skupien-
Rabian1,4, Sylwia Kedracka-Krok4, Karolina Wiatrowska2, Monika Bzowska2, Monika Machula2 
& Joanna Bereta2
IgM is a multivalent antibody which evolved as a first line defense of adaptive immunity. It consists of 
heavy and light chains assembled into a complex oligomer. In mouse serum there are two forms of IgM, 
a full-length and a truncated one. The latter contains μ’ chain, which lacks a variable region. Although μ’ 
chain was discovered many years ago, its origin has not yet been elucidated. Our results indicate that μ’ 
chain is generated from a full-length heavy chain by non-enzymatic cleavage of the protein backbone. 
The cleavage occurred specifically after Asn209 and is prevented by mutating this residue into any other 
amino acid. The process requires the presence of other proteins, preferentially with an acidic isoelectric 
point, and is facilitated by neutral or alkaline pH. This unique characteristic of the investigated 
phenomenon distinguishes it from other, already described, Asn-dependent protein reactions. A single 
IgM molecule is able to bind up to 12 epitopes via its antigen binding fragments (Fabs). The cleavage 
at Asn209 generates truncated IgM molecules and free Fabs, resulting in a reduced IgM valence and 
probably affecting IgM functionality in vivo.
IgMs are the first antibodies produced by B-cells during immune response. They are very large proteins with a 
molecular mass (Mw) of about 1 MDa. A complete IgM molecule consists of three types of polypeptides: heavy 
chains, light chains and J-chain. N-terminal parts of each heavy and light chains consist of unique variable 
domains that form an antigen binding site. The remaining parts of the heavy and light chains are constant regions 
shared by all IgMs. The heavy chain of IgM has four constant domains, called CH1-CH4, and the light chain has 
one, CL. Two heavy chains and two light chains associate into a monomeric IgM. CH4 domain has an intrinsic 
ability to oligomerize1 and induces formation of IgM penta- or hexamers. IgM oligomers are covalently linked 
via disulfide bonds and their structures resemble snowflakes. J-chain is a 15 kDa polypeptide crucial for IgM 
secretion into mucosa2.
Mouse IgMs are widely used in research and diagnostics, especially in blood typing. Moreover, IgMs, includ-
ing those of mouse origin3,4, are considered as promising therapeutic agents with strong cytotoxic potential. The 
framework of IgM may be very useful in therapies due to its high avidity and fast pharmacokinetics. However, 
the clinical application of IgMs is challenging because of many problems with production and downstream 
processing5,6.
High Mw, heavy glycosylation, dozens of disulfide bonds and a complex oligomeric structure make IgMs very 
difficult to express, purify and formulate. IgMs activity is rapidly lost through aggregation that is predominantly 
disulfide driven7. In the case of mouse IgMs we observed additional phenomenon adversely affecting their activ-
ity: the heavy chain N-terminus trimming, which yields 55 kDa μ’ chain7.
The first description of μ’ chain was given by Marks and Bosma in 19858. Although the authors proved that 
μ’ chain is a fragment of a heavy chain lacking a variable region, the origin and exact sequence of μ’ chain were 
unknown.
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To date, apart from the mouse μ’ chain, at least four examples of a truncated IgM heavy chain have been 
reported. In two of them the shortened variants are produced via alternative splicing. Each domain of the IgM 
heavy chain is encoded by a separate exon. In human B-cells the exon coding for a variable domain may be omit-
ted during pro-mRNA splicing9 resulting in the heavy chains that lack this domain. Alternative splicing was also 
postulated as a mechanism of μ’ chain production in mouse cells8 but this hypothesis failed to be confirmed9.
Another example is an IgM variant produced by bony fish (teleosts). The variant is shortened on C-terminus; 
it lacks CH4 domain and is a part of the B-cell receptor (BCR) on fish lymphocytes. Bony fish have an exceptional 
IgM pre-mRNA splicing pattern unique among vertebrates10.
The other two examples concern the generation of a shortened mouse IgM heavy chain during B-cell differ-
entiation. This kind of molecule may result from a defective genomic rearrangement11. Genes coding for immu-
noglobulins are formed during B-cell development in a multi-step process called genomic rearrangement. The 
rearrangement may be stopped by an incorrect assembly, which may lead to production of a heavy chain short-
ened on N-terminus.
Also, IgM heavy chain that does not associate with a light chain may be structurally labile and prone to pro-
teolytic truncation12. The proteolysis was observed intracellularly at an early stage of B-cell development, before 
the cell started to produce a light chain. Mw of the heavy chain fragment generated by the action of a putative 
intracellular protease was approximately 48 kDa, which is different from the estimated Mw of μ’ chain (55 kDa).
We have previously reported that the quantity of μ’ chain increases during storage of IgM-based blood typing 
reagents7. Our results indicated that μ’ chain is generated extracellularly from full-length IgM in the presence 
of serum or in the presence of bovine serum albumin (BSA) preparation, which, apart from albumin, contains 
numerous other proteins. We have observed that the accumulation of μ’ chain adversely affected the activity of 
the IgM reagents. Substantial amount of μ’ chain was detected also in normal mouse serum7,8, but its influence on 
immune response and IgM activity in vivo is unknown.
Our research aimed to identify the factors involved in μ’ chain generation. We scrutinized the biochemical 
properties of μ’ chain and determined its sequence. The specific cleavage site, Asn209 in CH1 domain, suggested 
an enzyme-mediated process. However, our thorough search for the enzyme responsible for IgM truncation led 
us to the conclusion that the generation of μ’ chain is a non-enzymatic process. In the course of our work we also 
developed a set of IgM muteins that are resistant to truncation.
Results
Mouse μ’ chain is a heavy chain fragment lacking a variable region and a large part of CH1 domain. 
We began our research from biochemical analyses of μ’ chain. Firstly, we removed potential N-glycans from three 
different IgMs: MM-30, O10, and Q6, using PNGase F. The experiment revealed that μ’ chain is a glycosylated 
protein consisting of a polypeptide with Mw of about 40 kDa and several N-glycans, which total Mw is approxi-
mately 15 kDa (Fig. 1a). Assuming that Mw of a mammalian N-glycan is approximately 3 kDa, we estimated that 
5 N-glycans are attached to the μ’ chain. Mw of μ’ chain polypeptide corresponds to three domains of IgM heavy 
chain. Considering that the full-length IgM heavy chain consists of five similar-size domains and six N-glycans 
attached to constant domains, the analysis suggested that μ’ chain may arise in two different ways: (i) the molecule 
is devoid of both N- and C-termini; the variable and CH4 domains are cut off from the full-length heavy chain or 
(ii) truncation occurs only on N-terminus and variable and CH1 domains are removed.
To verify which domains are present in μ’ chain we performed polypeptide sequencing using mass spectrom-
etry (MS). The μ’ chains derived from O10 and Q6 antibodies were fragmented with trypsin or V8 protease. 
Figure 1b presents coverage and the numbers of measured peptides derived from the full-length heavy chain. 
Peptides originated from the CH2 and CH3 domains are prevalent independently on the fragmentation method. 
In contrast to V8 digestion results, CH4-derived peptides were rarely detected after trypsin cleavage. CH4 domain 
has only few unevenly distributed trypsin cleavage sites. Long peptides are difficult to be efficiently sequenced 
with MS and probably for this reason we did not observe CH4-derived peptides within tryptic fragments. For 
both enzymes, the least frequently represented peptides came from variable and CH1 domains. These results 
indicated that μ’ chain is formed from a full-length heavy chain by cutting off the variable and CH1 domains. 
Tiny amounts of peptides derived from CH1 domain in O10 samples may result from high sensitivity of MS and 
incomplete separation of full-length and truncated heavy chains during SDS-PAGE preceding the analysis.
Edman sequencing of μ’ chain N-termini of three different IgMs confirmed the results of MS. (Fig. 1c). The 
obtained sequences were exactly the same for the three analyzed antibodies and their alignment with the sequence 
of mouse IgM constant region (UniProtKB record P01872; IGHM_MOUSE) showed that μ’ chain arises by cleav-
age after Asn209 (EU numeration13; Asn209 corresponds to Asn96 in the UniProtKB record). The scissile peptide 
bond between Asn209 and Arg210 is localized within a solvent accessible loop (Fig. 1e) and precedes the linker 
between CH1 and CH2 domains (Fig. 1f). The cleavage site is surrounded by basic residues (Fig. 1g).
It has been shown that the truncated human IgM heavy chain is produced by alternative splicing9. To exclude 
the possibility that we identified an alternatively spliced variant of the mouse IgM heavy chain we translated in 
silico the exon coding for CH1 domain (Fig. 1h). The putative cleavage site is localized 9 residues before the end 
of CH1 domain determined on the basis of exon splicing.
In this part of our research we discovered that μ’ chain is a fragment of IgM heavy chain lacking a variable 
region and a large part of CH1 domain. The μ’ chain is generated post-translationally by precise cleavage just 
before the linker between CH1 and CH2 domains.
Mutating Asn209 prevents cleavage of mouse IgM heavy chain. Next, we aimed at elucidating the 
mechanism of truncation of the IgM heavy chain. We assumed that the cleavage is catalyzed by a serum pro-
tease7 and, to determine its specificity, we identified the residues within P6-P4′ sequence essential for trimming 
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(Fig. 2a). Alanine screening revealed that among the investigated positions only Asn209 at P1 is crucial for this 
process (Fig. 2b).
In many antibodies asparagine is spontaneously deamidated into aspartic acid14. This process is relatively 
slow15 and progresses during protein storage14. We hypothesized that the truncation of the IgM heavy chain 
may follow deamidation of Asn209, which could be the rate-limiting step. Thus, we generated the Asn209Asp 
mutein and incubated it in neutral or acidic pH, in which the Asp residue is deprotonated or protonated, respec-
tively. The mutein was resistant to fragmentation under both conditions (Fig. 2c). We also introduced an artificial 
N-glycosylation site on Asn209 by mutating Asp212 into Ser. The N-glycosylation on Asn209 was confirmed by a 
slight band shift to higher molecular mass in SDS-PAGE gel (Fig. 2c). The N-glycosylation of Asn209 also blocked 
IgM heavy chain cleavage (Fig. 2c).
Considering that many proteases are not able to hydrolyze a peptide bond formed by imine group of proline, 
we generated additional P1’ mutant Arg210Pro to verify whether a putative IgM-specific protease belongs to this 
category. However, despite many efforts, we were not able to efficiently express this IgM variant (Fig. 2c).
The results indicated that IgM truncation depends on the particular Asn residue, which provides the carboxyl 
group to the cleaved peptide bond. To confirm this observation we mutated Asn at P1 site into all other 19 protein 
amino acids and analyzed stability of generated muteins. The experiment proved that Asn209 is essential for IgM 
cleavage (Fig. 2d).
Despite the fact that in human IgMs Asn is present at the 209 position and is followed by a basic Lys residue, 
human IgMs are not susceptible to extracellular truncation in human serum (data not shown). To answer the 
Figure 1. Mouse μ’ chain is generated by specific cleavage after Asn209 in IgM heavy chain constant region. (a) 
Estimation of μ’ chain molecular mass. Three different IgMs were deglycosylated using PNGase F. Glycosylated 
μ‘ chain is a 55 kDa protein. It consists of a ∼40 kDa polypeptide and five N-glycans, which total Mw is about 
15 kDa. The gel was stained using silver nitrate. deglyc. – deglycosylated; HC – heavy chain; LC – light chain. 
(b) MS analysis of μ’ chains derived from O10 and Q6 IgMs. The charts present sequence coverage and numbers 
of detected peptides obtained from μ’ chain by trypsin- or V8 digestion. (c) N-terminal sequences of μ’ chains 
derived from three different IgMs determined by Edman degradation. Grey letters indicate uncertain residues. 
(d) Domains of full-length IgM heavy chain. Arrowheads indicate N-glycosylation sites. The site of cleavage 
resulting in μ’ chain is shown with an arrow. (e) Model of CH1 and CH2 domains of mouse IgM. Asn209 is 
in a solvent accessible loop. The model was generated using I-TASSER server47,48 and visualized in PyMOL 
(Schrödinger). (f) Asn209 precedes the CH1-CH2 linker. (g) Asn209 is surrounded by charged amino acids. (h) 
IgM heavy chain cleavage occurs within CH1 domain after Asn209 (marked in bold). There is a polymorphism 
in amino acid residue 209 between mouse strains C57 (Lys209) and Balb/c (Arg209).
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question whether the sequence surrounding the scissile bond or other parts of the molecule are responsible for 
mouse IgM susceptibility to truncation, we generated a chimeric molecule: mouse IgM with the linker between 
CH1 and CH2 domains along with the preceding loop substituted for the human IgM-derived sequence. The 
obtained mouse/human IgM was resistant to fragmentation in the presence of serum (Fig. 2e), indicating that the 
features promoting cleavage are located within the replaced fragment (amino acids 203–239).
Trimming of IgM correlates with loss of IgM activity7. We believe that the obtained muteins resistant to the 
truncation of a heavy chain may address flaws of IgMs application in diagnostics or basic research5–7. Importantly, 
as presented in Fig. 2f, the introduced mutations did not affect affinity of IgM to the antigen.
We concluded from this part of the study that trimming of the mouse IgM heavy chain results from the 
exceptional sequence of the C-terminal fragment of its CH1. We also proved that cleavage could be prevented by 
mutating Asn209.
Mouse IgM cleavage is a non-enzymatic process. We have previously reported that IgM truncation 
occurs in mouse serum7. Moreover, we traced FBS as a source of the cleaving factor in the case of IgMs secreted 
by hybridoma cells. The truncation was also observed in the presence of BSA obtained from bovine serum by 
heat fractionation. The BSA preparation contained numerous other proteins, thus we initially assumed that the 
cleaving factor co-purifies with BSA7.
Figure 2. Asn209 in the constant region of mouse IgM heavy chain is crucial for extracellular cleavage of the 
antibody. (a) The scheme presents residues from the loop containing Asn209 that were subjected to alanine 
screening. Glycine residues at P3 and P4 were not mutated. (b–e) Stability of mutated IgMs in the presence 
of serum. μ’ chain was detected using western blotting. The samples were probed with anti-mouse-IgMκ 
antibody. (b) Stability of muteins generated using alanine screening. (c) Stability of Asn209Asp and Asp212Ser 
(N-glycosylated Asn209) muteins. Asn209Asp mutein was incubated at neutral or acidic pH. Despite many 
efforts we were not able to produce Arg210Pro mutein. Asn209 glycosylation was confirmed by a band shift 
visible on membrane stained with Coomassie Brilliant Blue (CBB). The full-length membrane is presented in 
Supplementary Figure S2. Contrast of the Coomassie-stained membrane was enhanced equally across the entire 
image. All bands remained visible after the digital processing. (d) Stability of IgMs with P1 position mutated 
into other 19 amino acids. Analyzed samples were derived from the same experiment but resolved in two 
different gels because of the limited number of wells. The figure presents images of two different blots processed 
in parallel. (e) Stability of chimeric mouse/human IgM. (f) Functional affinity of mutated IgMs analyzed by 
ELISA on immobilized human erythrocytes bearing a cognate antigen7. The results are representatives of three 
(b and e) or two (c,d,f) independent experiments. Bands corresponding to HC in blots presented in panels c and 
d are slightly overexposed in order to make μ’ signal more visible. Serial exposures of the overexposed blots are 
provided in Supplementary Figure S3.
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High specificity of the cleavage pointed to an enzyme-mediated process. We searched MEROPS database16 for 
proteases specific to Asn at P1. Among few hits there was only one mammalian enzyme – legumain – a lysosomal 
cysteine protease17 that is also present in serum18. We hypothesized that legumain is the factor cleaving IgMs.
To verify this hypothesis, we inhibited legumain present in serum using alkylating agents (Fig. 3a) and then 
analyzed whether these reagents prevented IgM trimming. Moreover, we tried to cleave IgMs with active recom-
binant legumain (Fig. 3b). The results of these experiments were negative and indicated that legumain is not 
involved in IgM truncation.
To identify the class of a putative protease involved in IgM cleavage we incubated the antibody with FBS (as 
a source of the enzyme) and a panel of protease inhibitors (Fig. 4a). We observed that protease inhibitor cocktail 
apparently limited IgM cleavage, but the inhibitors used as single agents were insufficient to block trimming. 
Although we tested 18 different inhibitors, which are listed in Methods section, we did not identify any specific 
inhibitor preventing IgM trimming. In our previous study we observed that protease inhibitor cocktail strongly 
enhances IgM aggregation7. Alike, in the present experiment the diminished accumulation of μ’ chain in samples 
containing the cocktail was accompanied by increased levels of aggregates and decreased levels of a full-length 
heavy chain (Fig. 4a). Therefore, we believe that low levels of μ’ chain in the cocktail-containing samples resulted 
either from the diminished cleavage due to IgM aggregation or from possible high propensity of μ’ chain to 
aggregate in the presence of the cocktail rather than from the specific action of particular inhibitors. Therefore, 
we decided to search for the cleaving factor ab initio.
Firstly, we analyzed the influence of pH on IgM cleavage (Fig. 4b). IgMs were trimmed more efficiently at 
neutral and alkaline pH than under acidic conditions. The result suggested that the cleaving factor cannot be a 
lysosomal protease.
Then, we analyzed whether the cleaving factor is secreted or is an intracellular protein occasionally released 
from dying cells. Most of the serum proteins are produced by hepatocytes. Thus we verified if the Hep G2 human 
hepatoma cell line secretes the cleaving factor. IgM trimming occurred during incubation of the antibody both in 
Hep G2 conditioned medium (Fig. 4c) and in Hep G2 cell lysate (Fig. 4d). Moreover, the cleaving factor could be 
concentrated by ultrafiltration using a 3 kDa cut-off membrane (Fig. 4c). The filtrate containing molecules with 
Mw lower than 3 kDa and negligible amount of proteins (∼20 μg/ml) did not induce IgM trimming, indicating 
that the cleaving factor is not a low Mw compound.
Following up on these results, we tried to fractionate the conditioned medium on Cibacron Blue resin, which 
binds many enzymes as well as serum albumin19. The results indicated that the resin retained the cleaving factor, 
because the flow-through fraction did not induce IgM truncation (Fig. 4d). The conditioned medium was also 
fractionated using glycoprotein-specific Concanavalin A resin. We observed that both the glycoprotein fraction 
and the flow-through fraction induced IgM truncation (data not shown). Although we searched for a specific 
factor involved in IgM trimming, the results suggested that there are different, secreted and intracellular, glyco-
sylated and non-glycosylated, factors able to induce this phenomenon. This observation led us to the question on 
whether any protein could trigger μ’ generation.
To gain insight into IgM stability in the presence of other proteins we incubated IgM with an excess of BSA 
or other purified proteins that were readily available in our laboratory. The physiological serum level of albumin 
is about 20 mg/ml20. IgM concentration in non-immunized mouse serum reaches about 0.2 mg21 and increases 
after exposure to an antigen7. In our experiments we preserved the physiologic ratio between concentrations of 
albumin and IgM (100:1) and, for the experimental convenience, the total protein concentration was about 20 
times lower than that in normal mouse serum.
This experiment revealed that IgM cleavage was induced, beyond BSA preparation, also by other acidic pro-
teins: protein A, infrared fluorescent protein (IRFP) and soybean trypsin inhibitor (Fig. 4e).
We also incubated IgMs with three basic proteins: salmon protamine, hen egg lysozyme and mature vascular 
endothelial growth factor C (VEGF-C). In the case of protamine we observed precipitates, which quantity cor-
related with a concentration of protamine. Non-precipitated samples with the lowest protamine concentration 
(0.1 mg/ml) did not contain increased amount of truncated IgM (Fig. 4f). Lysozyme did not induce IgM trimming 
Figure 3. Legumain does not cleave mouse IgM. (a) IgM cleavage in serum treated with alkylating agents. 
Alkylating agents, such as iodoacetamide or NEM, are potent inhibitors of legumain – a cysteine protease 
specific to Asn at P1 site. Activity of legumain present in FBS was tested using fluorogenic substrate Z-Ala-Ala-
Asn-AMC. Samples were analyzed using western blotting with anti-mouse IgMκ antibody. The full-length blot 
is presented in Supplementary Figure S2. (b) Recombinant legumain did not cleave IgMs. The gel was stained 
with Coomassie BB. (a and b) Representatives of two independent experiments are shown.
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(data not shown). In samples with VEGF-C we did not observe precipitates, but IgM signals on exposed blots 
were substantially decreased (Supplementary Figure S1).
Presented results indicate that although extracellular truncation of mouse IgMs is a non-enzymatic process it 
depends on the presence of proteins with not yet fully defined characteristics. Our further studies aim to elucidate 
the mechanism of this cleavage.
Discussion
Asn is a highly reactive residue that frequently contributes to inactivation and degradation of many proteins, 
including antibodies22–24. Asn is prone to non-enzymatic deamidation. Mechanism of the reaction is dependent 
on pH [reviewed in23]. Under acidic conditions, the side-chain amide bond is attacked by a water molecule, yield-
ing ammonia and aspartic acid. At neutral or basic pH, two reactions are possible: (i) deamidation or (ii) cleavage. 
(i) The nitrogen in the peptide bond on the carboxyl side of Asn attacks the carbon in the amide group of Asn 
resulting in ammonia and a cyclic succinimide intermediate. The cyclic imide undergoes subsequent reactions 
involving isomerization or transpeptidation. (ii) Alternatively, the nitrogen in the amide group of Asn attacks the 
carbonyl in the following peptide bond. The reaction cleaves the protein backbone and yields two polypeptides, 
one of which ends with succinimide. The reactions (i) and (ii) compete at neutral or alkaline pH, but deamida-
tion is favored over cleavage25 due to lower activation energy26. Deamidation at neutral or basic pH starts from 
deprotonation of the attacking nitrogen of the peptide bond. Cleavage occurs only if nitrogen deprotonation is 
Figure 4. Factors affecting IgM cleavage. Samples were analyzed using western blotting with anti-mouse IgMκ 
antibody. (a) Serum-induced IgM cleavage in the presence of protease inhibitors. Presented result is an example 
of many experiments, in which also other inhibitors, all listed in Methods section, were used. None of the 
single inhibitors prevented IgM trimming. (b) Serum-induced IgM cleavage at different pH. Standard sample – 
medium without additional buffer. (c and d) IgM cleavage induced by serum-free medium collected from Hep 
G2 cell culture. The medium was concentrated by ultrafiltration with 3 kDa cut-off. Cibacron Blue resin removes 
a factor cleaving IgM from the medium (d). The image in panel c combines data extracted from one blot 
presented in full in Supplementary Figure S2. (e) IgM cleavage induced by various proteins. IgM was incubated 
with a hundredfold excess of the indicated proteins. Samples were analyzed in duplicates or triplicates. (f) 
IgM stability in the presence of protamine. Representatives of ten (a), two (b,e,f), or four (c,d) independent 
experiments are shown.
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hampered by e.g. Pro or a bulky side chain on the carboxyl side of Asn27. There is also a report suggesting that the 
protein tertiary structure may promote cleavage26.
Here we report non-enzymatic cleavage of the mouse IgM heavy chain after Asn209. Initially, we assumed that 
IgM truncation is catalyzed by a protease. However, we excluded involvement of legumain, the only known mam-
malian Asn (P1)-specific protease and we found that none of the inhibitors from the set that covered all protease 
classes was able to limit IgM trimming.
Observed dependence on neutral or alkaline pH suggests that IgM truncation may involve direct 
Asn-mediated cleavage or cyclic imide formation followed by other reaction(s) resulting in the peptide bond 
scission. The scissile bond in the IgM molecule is between Asn209 and Arg210. According to reports evaluating 
the influence of amino acids on the carboxyl side of Asn on its reactivity28,29, Arg210 may have two effects: a steric 
hindrance and base catalysis. Arg has a large side chain which may interfere with nitrogen deprotonation in a 
preceding peptide bond. A positive charge of Arg210 may also enhance nucleophilicity of Asn209 amide group, 
thus promoting the side-chain amid nitrogen attack on a carbonyl group in the peptide bond. Asn209 in folded 
IgM is surrounded by four basic residues: Lys201, His204, Lys208 and Arg210, which probably strongly influence 
its reactivity. Importance of basic amino acids in Asn-mediated peptide bond cleavage is described for inteins 
[reviewed in30]. Inteins are self-splicing proteins, which in their multi-step self-processing employ peptide bond 
cleavage after Asn by the mechanism described above as (ii). Inteins catalyze Asn-dependent scission through a 
unique three-dimensional structure preventing deamidation. The basic residues near Asn209 in IgM may pro-
mote cleavage in a similar way.
However, deamidation of Asn and Asn-dependent cleavage of a protein backbone are intramolecular pro-
cesses, which do not require other proteins and do not depend on protein concentration22. Conversely, IgM trun-
cation was observed only in the presence of other proteins. Purified IgMs even at a concentration of 250 μg/ml 
were not truncated unless incubated with serum, BSA7 or certain other proteins. We compared IgM trimming 
in the presence of BSA, IRFP, protein A and soybean trypsin inhibitor. Although all these proteins induced IgM 
cleavage, their efficacy was diverse. IgM trimming was induced most efficiently by BSA obtained from serum 
using heat treatment. The heat fractionation results in many impurities in the final preparation. Thus, we previ-
ously hypothesized that IgM cleavage is catalyzed by a protease co-precipitating with BSA7. However, the results 
obtained with IRFP, protein A and soybean trypsin inhibitor suggest that many non-enzymatic proteins may 
induce IgM trimming.
The analyzed proteins were acidic, with pI equal to or lower than 5.7 (5.7 – IRFP; 5.11 – protein A; 4.7 – BSA; 
4.5 – soybean trypsin inhibitor). We also tried to use basic proteins: protamine (pI ~13), lysozyme (pI 11.4), and 
VEGF-C (pI 8.3). At high concentrations (>1 mg/ml) protamine precipitated during incubation with IgM, but 
at lower concentrations it neither influenced IgM quantity nor stimulated its trimming. Lysozyme also did not 
induce IgM trimming. In the presence of VEGF-C we observed a substantial loss of IgM. Because we did not 
observe precipitates in the samples with VEGF-C, we suppose that VEGF-C may enhance generation of IgM 
complexes unable to penetrate the gel.
What could be the mechanism of protein-induced IgM trimming? A tempting explanation is that a pro-
tein added to IgM solution may prevent Asn209 deamidation thereby shifting the balance towards cutting. 
Alternatively, the accompanying protein may induce a structural change in the IgM molecule which allows trun-
cation. IgMs are complex proteins that form various types of oligomers5,6. According to the theory of molecular 
crowding [reviewed in31], the structure and oligomeric state of a protein may be modified by the presence of other 
proteins or crowding agents. In line with that, molecular crowding in serum modulated the fate of succinimide 
intermediate formed during Asn deamidation in a therapeutic antibody24. It is also possible that the added protein 
is directly involved in non-enzymatic peptide bond cleavage via a currently unknown mechanism.
Some authors consider Asn-dependent cleavage as a post-translational modification, which relates to protein 
maturation rather than degradation32–36. In the described examples the process was slow with a half-time ranging 
from about 200 to more than 10,000 days15. Thus, the Asn residue acted as a molecular clock enabling modifi-
cation of a protein for a long time after its translation. Because of time requirements, Asn-dependent cleavage 
might be important in long-living polypeptides, e.g. proteins of the eye lens. At least two of them are subject to 
the Asn-dependent cleavage: crystallins35 and aquaporin-032. This process modified their stability, packing and 
function and is believed to orchestrate lens development and participate in its ageing33,34,36.
The calculated half-life of mouse IgM in the circulation is about 2 days37. Despite the short life-time an evident 
amount of μ’ is constantly present in mouse sera7,8, indicating that truncation of IgM is faster than the known 
Asn-dependent peptide bond cleavage in other proteins. If the IgM trimming proceeds via already known reac-
tion (ii), our results indicate that the process is accelerated by other proteins by a yet unrecognized mechanism. 
We cannot exclude that the phenomenon may be related to weak, non-specific catalytic capability of one or more 
serum proteins. Notably, serum albumins from a number of species are known to be able to catalyze certain 
reactions38. It is also possible, that IgM truncation occurs via a completely different reaction depending on labile 
Asn209.
A substantial amount of μ’ chain in mouse serum suggests that IgM truncation may be physiologically rele-
vant. The identified site of heavy chain trimming is within CH1 domain, just before the linker joining CH1 with 
CH2. A cleavage at this site should produce a free antigen binding fragment (Fab) and a truncated heavy chain, 
which still remains within the oligomeric IgM. Both products may act as negative regulators of early immune 
response. The Fab fragment may bind to a cognate epitope and decrease antigen availability for other immuno-
globulins. Truncated IgM has reduced avidity thus its interaction with an antigen is weakened. IgMs bound to 
multiple surface antigens e.g. on a bacterial surface are potent activators of the complement cascade, which leads 
to pathogen elimination. According to the current view, the complement activation requires a change in IgM 
conformation induced by antigen binding39. Binding sites for C1q, the first element of the complement cascade, 
are hidden in IgM structure and are exposed or formed only upon antigen binding39. IgM trimming resulting in 
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removal of Fab may reduce IgM competence to activate complement. However, according to another model of 
complement activation by IgM40, spatial fluctuations of Fab fragments prevent C1q binding. Sequestration of Fabs 
by cognate antigen molecules allows interaction between C1q and IgM. Thus, a truncated IgM may be even more 
potent complement activator than the non-trimmed molecule, because of reduced requirements for the epitope 
availability.
Enzymatic cleavage of IgM is used by Streptococcus suis during host (swine) invasion to evade immune 
response41,42. The bacteria produce highly specific IgM protease IdeSsuis, which cleaves porcine IgM heavy chain 
between CH2 and CH3 domains41. The action of IdeSsuis abrogated complement activation by porcine IgMs41. 
The products of IgM proteolysis induced by this pathogen differ from those of non-enzymatic IgM truncation in 
mouse, therefore the benefits or threats for mice, in which intrinsic IgM trimming occurs, are difficult to predict.
In conclusion, the mouse IgM heavy chain contains the labile Asn209 residue and is prone to non-enzymatic 
cleavage between CH1 and CH2 domains. The trimming occurs in neutral or alkaline pH and is induced by other 
proteins. The unique characteristic of this phenomenon suggests that it proceeds via currently unknown mecha-
nism and may have pronounced physiological implications.
Methods
Antibodies and enzymes. To provide scientific integrity, we used three IgMs with different variable 
regions: O10 and Q6 IgMs were produced and purified as previously described7 and MM-30 was purchased 
from Abcam Cat# ab18401, Lot# G232282-2, G232282-3. We observed differences in proportion of full-length 
and truncated heavy chains in various IgM preparations. Despite our efforts to use non-trimmed antibodies 
only, some samples contained low levels of μ’ at the beginning of the experiment, because truncation of IgMs 
occurs already during their production by hybridoma cells. The antibodies (6–12 μg) were digested with PNGase 
F (Promega) under denaturing conditions according to the manufacturer’s instruction. Legumain (Novoprotein) 
was activated as described by Zhang et al.43. The activity of the enzyme was verified using the fluorogenic sub-
strate Z-Ala-Ala-Asn-AMC (Bachem). The IgMs (10 μg) were incubated with activated legumain for 24 h at 37 °C 
and the substrate:enzyme mass ratio was 30:1. The incubation was performed in PBS and in the buffer suitable for 
legumain activity assays (20 mM citric acid, 60 mM Na2HPO4, 1 mM EDTA, 0.1% CHAPS, 1 mM DTT, pH 6.0). 
Samples of the IgMs treated with the enzymes were analyzed using SDS-PAGE and subsequent staining of the gels 
with silver nitrate or Coomassie Brilliant Blue.
Cells. Hep G2 cells (ATCC #HB8065) were cultured in DMEM with 1 g/l glucose (Lonza) and 10% FBS 
(Biowest) at 37 °C, 5% CO2 in a humidified incubator. To prepare serum-free Hep G2 culture, the cells were 
cultured to reach 90% confluency and then washed 5× with PBS and 2× with DMEM. DMEM with 1 g/l glu-
cose was added to the washed cells. Conditioned media were harvested after 24 h, centrifuged and filtered using 
0.22 μm filters. HEK293 cells and hybridoma clones producing O10 and Q6 IgMs were cultured as described pre-
viously7. All cell cultures were free of Mycoplasma spp. and were routinely screened using PCR with Mycoplasma 
rDNA-specific GPO1 and MGSO primers44.
Mass spectrometry. Bands were excised from SDS-PAGE gels and destained using 25% acetonitrile 
(ACN)/25 mM ammonium bicarbonate (ABC) and 50% ACN/25 mM ABC alternately. To reduce and alkylate 
proteins the samples were treated with 50 mM DTT/25 mM ABC for 45 min at 37 °C and then with 10 mg/ml 
iodoacetamide/25 mM ABC for 1 h at room temperature in the dark. Then, the bands were washed twice with 
50% ACN/25 mM ABC, dehydrated in 100% ACN and air-dried. Gel pieces were re-swelled in 50 mM ABC con-
taining 20 U of PNGase F (Promega) and incubated at 37 °C overnight. After that, they were extensively washed 
with ultrapure water, then with 50% ACN/25 mM ABC, dehydrated in 100% ACN and air dried. Gel pieces were 
re-swelled in 50 mM or 25 mM ABC containing Trypsin/Lys-C Mix (Promega) or V8 (Glu-C, Promega) enzyme 
and digestion was performed overnight at 37 °C. Then, trifluoroacetic acid (TFA) was added, peptides were col-
lected, vacuum-dried and suspended in loading buffer (2% ACN, 0.05% TFA) for LC-MS/MS analysis done with 
Q Exactive mass spectrometer (Thermo Scientific) coupled with nano-HPLC (UltiMate 3000 RSLCnano System, 
Thermo Scientific) through a Digital PicoView 550 ion source (New Objective). Peptides were loaded onto trap 
column (AcclaimPepMap100 C18, Thermo Scientific; ID 75 μm, length 20 mm, particle size 3 μm, pore size 100 Å) 
in 2% ACN/0.05% TFA at a flow rate of 5 μl/min and then separated on analytical column (AcclaimPepMapRLSC 
C18, Thermo Scientific; ID 75 μm, length 150 mm, particle size 2 μm, pore size 100 Å) using a 90 min gradient of 
ACN from 2% to 40% in the presence of 0.05% formic acid at a flow rate of 300 nl/min. Top 8 method was used 
for MS measurement with full MS and MS/MS resolution of 70 000 and 35 000 respectively. To identify pep-
tides, cRAP protein database containing O10 and Q6 sequences was searched by Mascot 2.5 (Matrix Science) via 
Proteome Discoverer 1.4 (Thermo Scientific).
Edman sequencing. Determination of N-terminal amino acid sequence by Edman degradation was per-
formed using PPSQ-31A automatic protein sequencer (Shimadzu). Before sequencing the proteins were sepa-
rated on a SDS-PAGE gel, electrotransferred on a Immobilon PSQ PVDF membrane (Millipore) and stained with 
Coomassie Brilliant Blue.
Generation of plasmids coding for mutated mouse IgMs. To generate cDNA coding for a 
full-length IgM heavy chain, cDNA coding for the heavy chain variable region of mouse M18 antibody7 was 
cloned into pFUSEss-CHIg-mM plasmid (Invivogen) using EcoRI and NheI restriction enzymes resulting in 
pFUSEss-CHIg-mM_M18 plasmid. Q5-based site directed mutagenesis kit (New England Biolabs) was used to 
introduce mutations within the constant region of mouse IgM encoded in pFUSEss-CHIg-mM_M18. A plasmid 
coding for chimeric mouse/human IgM heavy chain was generated by replacing the sequence encoding the linker 
between CH1 and CH2 domains (amino acid residues 90–115 in the sequence provided by UniProtKB record 
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P01872; IGHM_MOUSE) for the homologous human sequence (amino acid residues 90–115 in the sequence 
provided by UniProtKB record P01871; IGHM_HUMAN). A synthetic DNA coding for a fragment of mouse 
IgM with the human linker (Gene Art, Germany) was cloned into pFUSEss-CHIg-mM_M18 using endogenous 
restriction sites NcoI and BamHI. All generated plasmids were sequenced (Genomed, Poland) and are available 
via Addgene repository (plasmid numbers 91729–91756 and 91781) along with their complete sequences.
Expression of recombinant IgMs and analyses of their cleavage. All recombinant IgMs were tran-
siently expressed using adherent HEK293 cells cultured in DMEM supplemented with 10% FBS. The plasmids 
encoding IgM heavy chain (pFUSEss-CHIg-mM_M18 and its derivatives) were co-transfected with the plasmid 
coding for the cognate kappa light chain (pFUSEss-CLIg-mK_M187) using Lipofectamine2000 (Invitrogen). 
Media collected from cultures of the transfected cells were centrifuged at 10,000 × g, buffered with 20 mM 
Tris-HCl pH 7.4 or 20 mM acetate buffer pH 4.0 and then incubated for 72 h at 42 °C. The samples were immu-
noprecipitated using CaptureSelect IgM Affinity Matrix (Thermo Fisher Scientific). For efficient binding to 
the matrix, pH of the samples incubated under acidic conditions was adjusted to 7.4 with 2 M Tris. The matrix 
(20 μl) with bound IgM was washed 4 times with 1 ml of PBS containing 0.05% Tween-20 and then boiled with 
SDS-PAGE reducing loading buffer. The samples were analyzed by western blotting using HRP-labeled goat 
anti-mouse IgMκ antibody (AbD Serotec, Cat# 5276–2504).
Analyses of factors affecting IgM cleavage. Several factors affecting IgM cleavage were investigated. 
IgMs were incubated under conditions described below at 42 °C for 72–96 h and then boiled with SDS-PAGE 
loading buffer. The quantities of emerging μ’ chain were estimated by western blotting using goat anti-mouse 
IgMκ antibody.
 (i) To inhibit activity of legumain, 50% FBS was treated overnight with 100 mM iodoacetamide (Sigma) in 
250 mM carbonate buffer, pH 8.0. Alternatively, 50% FBS was incubated with 50 mM N-ethylmaleimide 
(Sigma) in 250 mM phosphate buffer, pH 6.5. FBS samples were then dialyzed three times against PBS. 
Each time the volume of dialysis buffer was fifty-fold the volume of sample. O10 or Q6 IgM (200ng) was 
incubated in 20 μl of PBS with 1.5 mg/ml treated or control FBS and then immunoprecipitated as described 
above. Legumain activity in the samples was verified using Z-Ala-Ala-Asn-AMC according to the protocol 
of the substrate’s manufacturer.
 (ii) In studies with protease inhibitors, MM-30, O10, or Q6 IgM (200 ng) were incubated in 20 μl of PBS 
with 5% FBS (Biowest) and one of the inhibitors: AEBSF, antipain, aprotinin, benzamidine HCl, bestatin, 
chymostatin, E-64, EDTA, ε-aminocaproic acid, iodoacetamide, N-ethylmaleimide, leupeptin, pepstatin A, 
phosphoramidon, soybean trypsin inhibitor (all from Sigma), phenantrolin (Bioshop), batimastat (Sigma) 
or the legumain-specific inhibitor MV02663045, which was kindly gifted by Prof. Colin Watts (School of 
Life Science, University of Dundee, UK). Cocktails of inhibitors (Sigma or Thermo Scientific) were added 
to some samples in each experiment. The inhibitors were used in two concentrations: one recommended 
by their supplier and the second that was 2–10 times higher than the recommended one.
 (iii) To analyze pH-dependency of IgM cleavage, 2.5 × 105 hybridoma cells secreting O10 or Q6 IgM were 
seeded in 1 ml of DMEM with 5% FBS. The cultures were harvested after 24 h and centrifuged at 1000 × g 
for 10 min. The supernatants were then buffered with 20 mM citrate buffer pH 4.0 or 5.0; 20 mM phosphate 
buffer pH 6.0 or 8.0; or 20 mM Tris HCl pH 10.0. The buffered samples were then incubated for 5 min or 
72 h.
 (iv) Experiments with Hep G2 cell line were performed to establish localization of the cleaving factor. 200 ng of 
purified O10 IgM was incubated with 20 μl of: fresh serum-free medium (control) or tenfold concentrated 
serum-free Hep G2 culture medium, or Hep G2 cell lysate (10 μg of protein) obtained by mild sonication 
of cells suspended in PBS. The medium was concentrated by ultrafiltration using a 3 kDa cut-off membrane 
(Millipore). In some experiments the medium was pretreated with Cibacron Blue 3GA agarose (Sigma).
 (v) Stability of IgMs in the presence of various proteins was also investigated. O10 or Q6 IgM (10 μg/ml) was 
incubated in 1 mg/ml solution of BSA obtained by heat-fractionation (Sigma) or highly purified IRFP 
(kindly provided by Jarosław Jucha from the Jagiellonian University in Kraków, Poland), lysozyme (Sigma), 
salmon protamine (Sigma), protein A (Thermo Scientific), soybean trypsin inhibitor (Sigma). VEGF-C 
was produced as previously described46 and used at a concentration of 200 μg/ml. Three different concen-
trations of protamine, 5, 1 and 0.1 mg/ml, were used. All solutions were prepared in PBS.
SDS-PAGE and western blotting. The analyses were performed as previously described7. The images 
were analyzed using Fusion Fx apparatus with the Fusion Capt Advance Fx5 program (Vilbert Lourmat, France). 
Unless otherwise stated, the acquired images were not processed.
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Mouse IgG3 is highly protective against several life-threatening bacteria. This isotype 
is the only one among mouse IgGs that forms non-covalent oligomers, has increased 
functional affinity to polyvalent antigens, and efficiently agglutinates erythrocytes. IgG3 
also triggers the complement cascade. The high efficacy of protection after passive 
immunization with IgG3 is correlated with the unique properties of this isotype. Although 
the features of IgG3 are well documented, their molecular basis remains elusive. Based 
on functional analyses of IgG1/IgG3 hybrid molecules with swapped constant domains, 
we identified IgG3-derived CH2 domain as a major determinant of antibody oligomer-
ization and increased functional affinity to a multivalent antigen. The CH2 domain was 
also crucial for efficient hemagglutination triggered by IgG3 and was indispensable for 
complement cascade activation. This domain is glycosylated and atypically charged. 
A mutational analysis based on molecular models of CH2 domain charge distribution 
indicated that the functional affinity was influenced by the specific charge location. 
N-glycans were essential for CH2-dependent enhancement of hemagglutination and 
complement activation. Oligomerization was independent of CH2 charge and glycosyla-
tion. We also verified that known C1q-binding motifs are functional in mouse IgG3 but 
not in IgG1 framework. We generated for the first time a gain-of-function antibody with 
properties transferred from IgG3 into IgG1 by replacing the CH2 domain. Finding that the 
CH2 domain of IgG3 governs unique properties of this isotype is likely to open an avenue 
toward the generation of IgG3-inspired antibodies that will be protective against existing 
or emerging lethal pathogens.
Keywords: igg3, oligomerization, multivalent antigen, polyvalent antigen, hemagglutination, ig constant region
inTrODUcTiOn
There are four subclasses of mouse IgGs: IgG1, IgG2a, IgG2b, and IgG3. Although structurally very 
similar, they significantly differ in their functions (1). Mouse IgG3s are particularly interesting, 
because they are able to form oligomers, which strongly influences their biological activities (2).
Mouse IgG3 was described for the first time almost 50  years ago (3) and different aspects of 
its biology have been investigated by several groups. The propensity of IgG3 oligomerization was 
noticed already by its discoverers (3). Then, other researchers reported cooperative binding of IgG3 
to a multivalent antigen (4,  5). Although the initial report on IgG3 oligomerization concerned 
molecules in solution (3), later studies revealed that binding to multivalent antigens promoted IgG3 
2
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intermolecular interactions, which in turn resulted in its increased 
functional affinity to the antigen (4). This phenomenon depended 
on Fc, because IgG3 F(ab’)2 fragments did not bind to the antigen 
cooperatively (4). However, the exact molecular mechanism of 
IgG3 oligomerization remains unknown.
IgG3 is a major component of cryoglobulins in mice (2). Cryo­
globulins are plasma proteins that reversibly precipitate at low 
temperatures or at high concentrations (6). Cryogenic activity of 
IgG3 was shown to correlate with its ability to oligomerize, with 
the presence of charged residues in the variable region and the 
level of sialylation (7).
Also, IgG3 was reported as exceptionally effective in preventing 
or fighting several life­threatening microbial infections, e.g., with 
Neisseria meningitidis (8) or Bacillus anthracis (9). A comp arison 
between the four mouse IgG subclasses with the same variable 
region specific to B. anthracis capsule proved that only IgG3 is 
protective against pulmonary anthrax in a mouse model (9). 
Importantly, mouse–human chimeric antibodies containing a con­
stant region of any human IgG subclass were not effective, although 
they had the same variable region as the protective mouse IgG3 
(10). These reports indicated that mouse IgG3 constant region has 
unique properties, but the authors only speculated about possible 
molecular mechanisms behind the observed phenomenon.
The exceptional characteristic of IgG3 was also confirmed 
by our previous report that among mouse IgGs recognizing a 
surface antigen of erythrocytes only IgG3s are able to agglutinate 
the cells (11). We rejected the hypothesis that IgG3­mediated 
hemagglutination results from oligomerization of the antibodies, 
because IgG3 F(ab’)2 was sufficient to trigger hemagglutination. 
Molecular modeling indicated that IgG3 has a larger span of Fab 
arms than other IgG subclasses. IgG3 has a long­upper hinge that 
may extend the Fab range, but whether this may account for the 
ability to hemagglutinate was not verified experimentally.
Here, we present the results of our attempts to find molecular 
determinants of the properties of mouse IgG3. Our experimental 
model comprised two antibodies (M18 and O10) specific to 
antigen B of the ABO blood group system (11). Antigen B is a pen­
tasaccharide O­glycan attached to numerous proteins and lipids 
on the erythrocyte surface. The large quantity and high density of 
the antigen, as well as a strong negative charge of the erythrocyte 
surface, could be considered as a safe and easy­to­handle model of 
a pathogen surface. We generated many muteins of IgG3 molecules 
and analyzed their functional affinity to the antigen as well as their 
ability to hemagglutinate and oligomerize. The results showed 
that IgG3­derived CH2 domain determines antibody oligomeri­
zation and increases its affinity to the antigen. This domain also 
strongly enhances agglutination of erythrocytes bearing B antigen. 
Moreover, we investigated complement activation by the muteins, 
and we confirmed that known C1q­binding motifs are functional 
in mouse IgG3 but not in the mouse IgG1 framework.
MaTerials anD MeThODs
generation of Vectors coding for  
antibody Muteins
Expression vectors coding for heavy chain muteins with swapped 
domains or mutated CH2 were generated using synthetic nucleic 
acids (Gene Art, Germany) cloned into pFUSEss­CHIg­mG1_
M18 (Addgene #82357) or pFUSEss­CHIg­mG3_M18 (Addgene 
#82356) plasmids (11). Only endogenous restriction sites present 
in the ORFs were used for cloning. Vectors coding for other 
muteins were prepared with Q5­based site directed mutagenesis 
kit (NEB). All plasmids coding for heavy chain variants of M18 
antibody are available via Addgene repository along with their 
full sequences and maps, accession numbers: 105849–105863. 
Plasmids encoding O10 antibody variants were obtained by 
replacing the sequence coding for M18 variable fragment with a 
corresponding O10­derived cDNA using EcoRI and AfeI restric­
tion sites in the vectors coding for M18 heavy chain variants. The 
sequence of O10 antibody is proprietary and cannot be disclosed. 
All plasmids were verified using Sanger sequencing (Genomed, 
Poland) or NGS (Addgene).
Production of antibodies
The recombinant antibodies were transiently expressed 
in HEK293T  cells cultured in DMEM with 4.5  g/l glucose 
(Lonza) supplemented with 10% FBS (Biowest). The cells were 
co­transfected with plasmids coding for a heavy chain and a 
cognate light chain using Lipofectamine2000 (Thermo) or PEI 
MAX (Polysciences, MW 40,000). In the case of M18 variants, 
the plasmid pFUSE2ss­CLIg­mK_M18 (Addgene, #82358) (11) 
coding for M18 light chain was used. A similar plasmid coding 
for O10 light chain was used for expression of O10 variants. 
Hybridoma­derived M18 IgG3 was produced as described pre­
viously (11). The antibodies were purified using CaptureSelect 
LC­kappa (mur) affinity matrix (Thermo) according to instruc­
tions of the supplier. Glycine–HCl (100 mM, pH 2.0) was used 
for elution.
Production of igg3 F(ab’)2
A sequence encoding IgG2b core hinge, HA tag and a stop 
codon was cloned into pFUSEss­CHIg­mG3_M18 downstream 
of the sequence coding for the upper hinge of M18. Sequences 
of the upper and core hinges of the antibodies are described by 
Dangl et al (12). Mouse IgG2b core hinge contains four cysteine 
residues that allow an efficient association of Fab’ fragments into 
F(ab’)2 (13). Recombinant F(ab’)2 was expressed as described for 
other antibodies. Alternatively, F(ab’)2 was produced by enzy­
matic digestion with IdeZ (NEB) according to the manufacturer’s 
protocol.
Measurements of antibody concentration
Antibody concentrations in cell culture media were measured 
using a standard sandwich ELISA on plates coated with sheep 
anti­mouse Fab polyclonal antibody (Jackson Laboratory, cat. 
#515­005­072, lot #105461). Goat anti­mouse kappa polyclonal 
antibody (1:3,000, BioRad, cat. #105008, batch #160617), HRP­
labeled streptavidin (1:40,000, Sigma), and the TMB substrate 
for HRP (BD Bioscience) were used for detection. The HRP­
dependent colorogenic reaction was stopped with 1  M HCl, 
and the absorbance at 450  nm was read using the microplate 
spectrophotometer Synergy H1 operated by Gen5 2.00 Software 
(BioTek). Purified M18 (IgG3) and MCP21 (IgG1, Sigma) were 
used as standards. Concentrations of muteins were calculated 
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based on their Fab type (IgG1­ or IgG3­type Fab). BCA assay 
(Sigma) was used for measurements of purified antibody concen­
trations with bovine γ­globulin (Thermo) as a reference.
antibody Binding to immobilized 
erythrocytes
Polystyrene plates were coated with 50 µg/ml poly­l­Lys (Sigma) 
for 1 h at room temperature (RT). Then, 100 µl of 0.1% (hematocrit) 
suspension of red blood cells in PBS were added to the wells and 
the cells were allowed to settle for 1 h at RT. After gentle aspiration 
of the solution, the cells were fixed using 0.025% glutaraldehyde 
for 40 min. Endogenous peroxidase activity was blocked with 3% 
H2O2 for 1 h. The plates were blocked overnight with 0.2% gelatin 
in PBS containing 0.05% Tween­20 at 4°C. Then, the cells were 
incubated with serial dilutions of cell culture media containing 
analyzed antibodies followed by detection with anti­mouse kappa 
polyclonal antibody conjugated with biotin (1:3,000, BioRad) 
and HRP­labeled streptavidin (1:40,000, Sigma). All reagents 
were diluted in the blocking buffer. The colorogenic reaction 
was performed, and the absorbance at 450 nm was measured as 
described above.
c1q Binding
Duplicates of polystyrene plates were coated with 6  µg/ml 
of BSA conjugated with the discriminating trisaccharide of 
the B antigen (Dextra Laboratories, cat #NGP6323, batch 
#ATDX232­039) overnight at 4°C, blocked with 1% BSA in PBS 
(1 h) and incubated with serial dilutions of cell culture media 
containing O10 muteins (2 h). Then, one set of plates was used 
for evaluation of C1q binding by analyzed antibodies; and the 
plates were incubated with 2 µg/ml of C1q purified from human 
serum (Biorad, cat. #22215504, batch #130815; 2  h) and next 
with HRP­labeled anti­human C1q polyclonal antibody (1:400, 
Abcam, cat. #ab46191, lot #GR205436­5; 1  h). The second set 
of plates was used to analyze quantities of the muteins bound 
to the immobilized antigen; and the plates were incubated with 
anti­mouse kappa polyclonal antibody conjugated with biotin 
(1:3,000, BioRad, 2 h) and HRP­labeled streptavidin (1:40,000, 
Sigma; 1 h).
Absorbance of HRP product was measured as described 
above. Each incubation step was preceded by extensive washing 
with 0.05% Tween­20 in PBS. The antibodies, streptavidin, and 
C1q were diluted in 0.1% BSA in PBS. All incubations, except 
plate coating, were at RT.
The normalized C1q binding (a) was calculated by dividing 
the signal corresponding to C1q binding (b) by the signal cor­
responding to bound antibody (c).
 
normalized binding
bindingsignal
boundantibody si
C q a
C q b
1
1( ) = ( )
gnal c( ) 
Uncertainty of a (Δa) was calculated by exact differential. 
Uncertainties of b and c (Δb and Δc) equaled to standard devia­
tions of the absorbance measurements.
 uncertainty of a a
a
b
b a
c
c b
c
b
c
c∆ ∆ ∆ ∆ ∆( ) = ∂
∂
+
∂
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= + 2  
complement cascade activation
Washed human red blood cells suspended to a hematocrit of 2% 
were coated with 3 µg/ml or 1.5 µg/ml of the analyzed antibodies 
for 1.5 h at RT, washed twice with PBS and resuspended in PBS 
with Ca2+ and Mg2+. Then, the same volume of human comple­
ment serum (Sigma, cat. #S1764, lot #SLBS5471V, #SLBQ0752V 
or #SLBP0461V) diluted to 7 CH50 U/ml in PBS with Ca2+ and 
Mg2+ was added to the coated red blood cells. The samples were 
centrifuged after 2 h of incubation at 37°C, and the absorbance of 
released hemoglobin was measured in the supernatants at 540 nm.
red Blood cells and agglutination
Standard human red blood cells were purchased from Regional 
Centre of Blood Donation and Blood Treatment in Katowice, 
Poland. Agglutination tests were performed in 96­flat bottom 
plates. Serially diluted solutions of analyzed antibodies (100 µl) 
were gently mixed with 0.45% (hematocrit) suspension of red 
blood cells. The level of agglutination was analyzed using a phase­
contrast microscope after 20 min of moderate shaking. A six­point 
scale was used for evaluation of agglutination intensity: from 4+ 
(complete cell aggregation), to 3+, 2+, 1+, ± to a negative score. 
The agglutination score reflects both the size of aggregates and 
quantity of non­agglutinated cells.
igg3 self-association assay
Oligomerization of IgG3 was analyzed similarly to the method 
described by Abdelmoula et al (2). Three different concentrations 
of the purified domain muteins with M18 variable region (150, 
100, and 20  µg/ml) were incubated with non­mutated, bioti­
nylated IgG3 M18 (100 ng/ml) for 72–96 h at 4°C in the presence 
of 4% BSA (Sigma, cat. #A9576). Then, the antibody complexes 
were precipitated by adding 50% PEG­6000 (Sigma) to the final 
concentration of 7.5%. After 1 h of incubation on ice, the samples 
were centrifuged (30 min, 3,000 × g, 4°C). The supernatants were 
preserved for further analysis, and the precipitates were washed 
with ice­cold 7.5% PEG­6000 in PBS and centrifuged again 
(30 min, 3,000 × g, 4°C). Then, the precipitates were dissolved 
in PBS with 0.1% BSA by pipetting at 37°C. Biotinylated IgG3 in 
the precipitates and supernatants was quantified using ELISA on 
polystyrene plates coated with streptavidin (8 µg/ml, Thermo, cat. 
#434301, lot #RB233354). Bound biotinylated IgG3 was detected 
using rabbit monoclonal antibody M111­2 (1:1,000, Abcam, cat. 
#ab125904, lot #C050311, #GR157092­1) and HRP­labeled goat 
anti­rabbit polyclonal antibody (1:3,000, Sigma, cat #A6667). The 
absorbance of HRP product was measured as described above.
sDs-Page and Western Blotting
Samples were resolved in 8 or 12% polyacrylamide gels under 
non­reducing or reducing conditions according to the protocol 
of Laemmli (14). After wet electrotransfer onto PVDF mem­
brane and blocking with 4% skim milk in PBS, the samples were 
probed with anti­mouse kappa polyclonal antibody conjugated 
with biotin (1:3,000, BioRad) and HRP­labeled streptavidin 
(1:40,000, Sigma). Alternatively, rabbit anti­HA tag polyclonal 
antibody (1:10,000, Abcam, cat. #ab9110) and HRP­labeled goat 
anti­rabbit F(ab’)2 polyclonal antibody (1:10,000, Sigma, cat. 
FigUre 1 | Hemagglutination induced by M18 IgG3 and its F(ab’)2. (a) Integrity of generated F(ab’)2 was verified using SDS-PAGE. In the case of the purified 
antibody digested with IdeZ, the gels were stained with Coomassie Brilliant Blue (CBB). Recombinant F(ab’)2 was equipped with HA tag and its integrity was 
confirmed using Western blotting with anti-HA tag antibody. The molecular mass of non-reduced F(ab’)2 is about 120 kDa. HC, heavy chain; HC’, heavy chain 
fragments generated after IdeZ cleavage; LC, light chain; (B) Microscopic images of erythrocytes agglutinated by equal molar concentrations of IgG3 antibody  
and its F(ab’)2. The antibody fragment was obtained from native IgG3 using IdeZ digestion.
TaBle 1 | M18 full-length IgG3 and M18 IgG3 F(ab’)2 induced hemagglutination with different efficacy.
concentration (nM) score of hemagglutinationa concentration (nM) score of hemagglutination
native igg3 F(ab’)2 obtained using ideZ recombinant igg3 recombinant F(ab’)2
82.5 ++++ + 93 ++++ ±
41.3 ++++ ± 46.5 ++++ –
20.6 ++++ – 23.3 ++++ –
10.3 ++++ – 11.6 +++ –
5.2 +++ – 5.8 +++ –
2.6 +++ – 2.9 + –
1.3 ++ – 1.5 ± –
0.6 ± – 0.7 – –
0.3 – – 0.4 – –
aRepresentative results of three independent experiments.
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#A6667, lot #SLBG3029) were used. Mouse IgG3 heavy chain was 
detected using goat antiserum to mouse IgG3 (1:500, Sigma, cat. 
#ISO2) and rabbit anti­goat polyclonal antibody (1:5,000, Sigma, 
cat. #A4174). Bands were visualized using Immobilon Western 
Chemiluminescent Substrate for HRP (Millipore). The images 
were captured and analyzed using Fusion Fx apparatus with the 
Fusion Capt Advance Fx5 program (Vilbert Lourmat, France).
resUlTs
comparison of hemagglutination induced 
by igg3 and igg3 F(ab’)2
In our previous work, we reported that F(ab’)2 obtained from 
IgG3 induces agglutination of erythrocytes bearing a cognate 
antigen (11). However, as shown below, complete IgG3 aggluti­
nates erythrocytes more efficiently than its F(ab’)2, i.e., a much 
higher concentration of F(ab’)2 than that of the intact molecule 
is required for agglutination. We compared hemagglutination 
triggered by: (i) native, purified, full­length IgG3, and its F(ab’)2 
obtained by IdeZ protease digestion and (ii) culture media of cells 
producing recombinant IgG3 or recombinant F(ab’)2 (Table 1). 
Concentrations of IgG3 and F(ab’)2 in the media were measured 
using ELISA and equalized for the comparative tests. We verified 
the quality of analyzed proteins and confirmed that recombinant 
IdeZ protease, which cleaves IgG3 at a single site in its hinge 
region, generates homogeneous F(ab’)2 (Figures 1A,B). Based on 
this analysis, we estimated that IgG3 was about 32 to 64­times 
more potent than its F(ab’)2 in hemagglutination (Table  1; 
Figure  1B). The results indicate that the Fc of IgG3 strongly 
enhances hemagglutination induced by this isotype.
The ch2 Domain Derived From igg3 
enhanced hemagglutination efficacy  
of an antibody
Our previous attempts to explain the mechanism of IgG3­dependent 
hemagglutination brought us to the hypothesis that the elongated 
hinge of IgG3 determines its hemagglutination ability (11). In light 
of the new results, the hypothesis required revision. To elucidate 
FigUre 2 | Hemagglutination induced by IgG1 and IgG3 muteins. (a) Generated domain muteins and their nomenclature. (B) Microscopic images of 
hemagglutination induced by the domain muteins. All antibodies were used at a concentration of 1.5 µg/ml, except of O10 IgG1_CH2-3 that was used  
at 3 µg/ml. Scale bar—100 µm; (c) Hemagglutination induced by selected O10 muteins used at 10 µg/ml.
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which domains of IgG3 are crucial for its hemagglutination abil­
ity, we generated a panel of domain muteins of agglutinating IgG3 
and non­agglutinating IgG1 isotypes (Figure 2A). We generated 
pairs of IgG1 and IgG3 molecules with the same variable regions 
and with swapped: (i) hinge regions; (ii) hinge regions  +  CH1 
domains; (iii) CH2 domains, and (iv) CH3 domains and searched 
for muteins of two types: loss­of­function in the case of IgG3 and 
gain­of­function in the case of IgG1.
Preliminary experiments showed that hinge swapping between 
IgG1 and IgG3 hinders disulfide bonds formation between 
chains of the muteins (Figure S1 in Supplementary Material). 
However, the IgG1_h­3 and IgG3_h­1 variants were functional 
and their affinity to the antigen was similar to that of the parental 
molecules (shown in Figure 3). As demonstrated by Dall’Acqua 
et  al., immunoglobulins with modified hinges frequently form 
functional heterotetramers (HC)2(LC)2 despite the lack of 
disulfide bonds between the chains (15). Gel filtration confirmed 
that IgG1_h­3 and IgG3_h­1 have molecular mass greater than 
150 kDa and form stable (HC)2(LC)2 heterotetramers (data not 
shown). To make sure that the results of the following experiments 
are not the consequence of incorrect assemblies of the hinge­
swapped muteins, we also generated muteins with swapped frag­
ments comprising hinge regions and CH1 domains. All muteins 
were successfully expressed and their integrity was verified using 
SDS­PAGE and Western blotting (Figure S1 in Supplementary 
Material).
Then, we compared hemagglutination induced by the muteins 
(Tables 2 and 3; Figures 2B,C). The results showed that neither 
TaBle 2 | Scores of hemagglutination induced by M18 variants.
conc. (μg/ml) Parental iggs swap of hinge regions swap of ch1 + hinge 
domains
swap of ch2 
domains
swap of ch3 
domains
igg1 igg3 igg1_ 
h-3
igg3_ 
h-1
igg1_ 
ch1h-3
igg3_ 
ch1h-1
igg1_ 
ch2-3
igg3_ 
ch2-1
igg1_ 
ch3-3
igg3_ 
ch3-1
ia ii i ii i ii i ii i ii i ii i ii i ii i ii i ii
1.500 – – +++ ++ – – +++ +++ – – +++ +++ + + – + – ± ++ +++
0.750 – – +++ +++ – – + +++ – – ++ +++ – ± – – – – + ++
0.375 – – ++ +++ – – ± + – – + ++ – – – – – – ± ++
0.188 – – + ++ – – – – – – ± + – – – – – – – –
0.094 – – ± ± – – – – – – – – – – – – – – – –
0.047 – – – – – – – – – – – – – – – – – – – –
aResults of two independent experiments designated as I and II.
FigUre 3 | Antigen binding by the domain muteins. M18 and O10 antibodies are specific to B-antigen present on human erythrocytes. B-antigen is a 
pentasaccharide O-glycan. O10 antibody, but not M18, binds terminal fragment of the antigen, called B-trisaccharide. Antigen–antibody interaction was analyzed 
using ELISA on immobilized erythrocytes. In the case of O10, plates coated with BSA conjugated with the synthetic B-trisaccharide were also used. The plots 
present mean values from two independent experiments performed in duplicates. Results obtained for IgG1 and IgG3, the parental molecules, are presented on 
each plot to allow convenient comparisons.
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TaBle 3 | Scores of hemagglutination induced by O10 variants.
conc. (μg/ml) Parental iggs swap of hinge regions swap of hinge + ch1 
domains
swap of ch2 
domains
swap of ch3 
domains
igg1 igg3 igg1_h-3 igg3_h-1 igg1_
ch1h-3
igg3_
ch1h-1
igg1_
ch2-3
igg3_
ch2-1
igg1_
ch3-3
igg3_
ch3-1
ia ii i ii i ii i ii i ii i ii i ii i ii i ii i ii
3.000 – – ++ ++ – – +++ ++ – – +++ ++ + + – ± – + +++ +++
1.500 – – +++ +++ – – +++ ++ – – +++ ++ ± – – – – – + ++
0.750 – – ++ ++ – – ++ ++ – – + ++ – – – – – – ± ±
0.375 – – + + – – + + – – ± ± – – – – – – – –
0.188 – – ± ± – – ± ± – – – + – – – – – – – –
0.094 – – – – – – – – – – – – – – – – – – – –
aResults of two independent experiments designated as I and II.
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the CH1 domain nor the hinge determined the agglutination 
ability of IgG3. The introduction of the CH3 domain from IgG1 
into IgG3 resulted in a molecule with slightly reduced hemag­
glutination score but CH3 from IgG3 did not translate into IgG1 
ability of hemagglutination. In contrast, CH2 swapping led to the 
generation of IgG1 mutein (IgG1_CH2­3) that gained the ability 
of hemagglutination (Tables 2 and 3). Moreover, the paired IgG3 
mutein (IgG3_CH2­1) had about 16­times reduced hemaggluti­
nation score in comparison to the parental IgG3.
IgG1_CH2­3 as a gain­of­function mutein was particularly 
interesting, because it indicated that the CH2 domain of IgG3 is the 
one critical for hemagglutination. However, IgG1_CH2­3 aggluti­
nated erythrocytes with considerably lower score than native IgG3.
We also compared hemagglutination efficacy of native M18 
IgG3 and its deglycosylated form. Deglycosylated IgG3 agglu­
tinated erythrocytes about 16­times weaker than the native 
molecule (Table S1 in Supplementary Material).
To sum up, the ability of IgG3 to agglutinate erythrocytes results 
from its unique structure, in which the CH2 domain is especially 
important and strongly enhances the efficacy of the process. 
Although the IgG3 F(ab’)2 is sufficient to trigger hemagglutina­
tion, its efficacy is much lower in comparison to full­length IgG3, 
probably just due to the lack of the CH2 domain. The hinge region 
seems to have little influence on agglutination ability, because 
IgG3 with the IgG1­derived hinge agglutinated erythrocytes only 
slightly less effectively than the parental molecule.
igg3 constant Domains Modify Functional 
affinity to an antigen
There is a general agreement that the increased functional affinity 
of IgG3 results from an avidity effect caused by the interactions 
between the Fc fragments of the molecules (16). In line with that, 
we observed that IgG3 binds to erythrocytes much more effi­
ciently than IgG1 with the same variable region and much more 
efficiently than IgG3­derived F(ab’)2 (Figure S2 in Supplementary 
Material). Some authors discussed also the potential role of 
N­glycans in IgG3 unique properties (17, 18), but we did not 
observe any differences in antigen binding between control and 
deglycosylated antibody (Figure S2 in Supplementary Material).
Aiming to understand why IgG3 has increased functional 
affinity, we analyzed antigen binding by the domain muteins 
(Figure  3). The results showed that the hinge region of IgG3 
does not influence the functional affinity of the antibody, 
but muteins with the swapped CH1  +  hinge, CH2, or CH3 
domains had changed functional affinity. The introduction 
of IgG3­derived CH1  +  hinge or CH2 domain into the IgG1 
framework enhanced antigen binding in comparison to the 
parental IgG1. Conversely, the paired IgG3 muteins with IgG1­
derived CH1 + hinge or CH2 had reduced functional affinity. 
The swapping of the CH3 domains resulted in the IgG3 mutein 
with decreased affinity, but in the paired IgG1 mutein, the effect 
was not substantial. The calculated EC50 values of antigen bind­
ing for IgG3 muteins indicated that the CH2 domain had the 
strongest influence on IgG3­antigen interaction (Table 4). CH2 
swapping resulted in IgG3 muteins with 3–12 times decreased 
functional affinity.
Overall, the results indicate that the higher (in comparison to 
IgG1) functional affinity of IgG3 to its antigen does not depend 
on a separate constant domain of this isotype, but rather is an 
additive result of discrete properties of the all three constant 
domains CH1, CH2, and CH3, but not the hinge region. Of all 
the constant domains, CH2 contributes the most to the high 
functional affinity of IgG3.
Fc-Dependent Oligomerization of the 
Domain Muteins
The hallmark of mouse IgG3 is its ability to oligomerize. The 
process depends on Fc fragment, but its exact molecular mecha­
nism is unknown. We analyzed whether the domain muteins 
form non­covalent complexes using polyethylene glycol (PEG) 
precipitation with a labeled IgG3 probe (2). In comparison to the 
original method, we used biotinylated IgG3 instead of radiolabeled 
IgG3. The IgG3­biotin interacted with oligomerizing muteins and 
the complexes comprised the mutein and the probe. The com­
plexes were precipitated using PEG, and then, IgG3­biotin was 
quantified in precipitates and supernatants using ELISA. A high 
precipitate/supernatant ratio of IgG3­biotin quantities indicates 
that the mutein forms oligomers.
The experiment showed that 5 out of 10 analyzed molecules 
form PEG­precipitable oligomers—IgG3 (control) and all IgG3 
muteins but the one containing IgG1­derived CH2 domain and 
none of IgG1 muteins but the one with IgG3­derived CH2 domain 
FigUre 4 | Oligomerization of the domain muteins. The antibodies (M18 
variants, 150 µg/ml) were incubated at 4°C and oligomers were precipitated 
using PEG. Biotinylated IgG3 was used as a probe that oligomerized with the 
muteins and became a part of the complexes. The charts present results 
from two independent experiments. The results obtained for 100 and 20 µg/
ml of the muteins are shown in Figure S3 in Supplementary Material. A 
percentage of the total IgG3-biotin detected in the precipitates and the 
supernatants is presented in Figure S4 in Supplementary Material.
TaBle 4 | EC50 of mutein binding to the antigen calculated using data from Figure 3.
Variable region of the mutein and type of the antigen ec50 of mutein binding (nM)
igg3 igg3_h-1 igg3_ch1h-1 igg3_ch2-1 igg3_ch3-1
M18 (erythrocytes) 0.24 ± 0.02 0.38 ± 0.01 0.61 ± 0.03 0.86 ± 0.04 0.87 ± 0.07
O10 (erythrocytes) 0.81 ± 0.01 0.88 ± 0.02 2.05 ± 0.06 9.75 ± 2.04 3.60 ± 0.29
O10 (B-trisaccharide conjugated to BSA) 0.50 ± 0.04 0.38 ± 0.02 1.15 ± 0.06 1.40 ± 0.03 0.79 ± 0.06
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(Figure 4). Oligomerization did not depend on CH2 glycosyla­
tion (Figure S5 in Supplementary Material). The results indicate 
that the CH2 domain is crucial for oligomerization of IgG3.
complement activation by the  
igg1 and igg3 Muteins
Similar to human antibodies, there are pronounced differences 
between mouse IgG subclasses in their ability to trigger comple­
ment cascade. Mouse IgG3 activates complement efficiently, 
whereas mouse IgG1 does not. Although there are many excel­
lent reports concerning correlation between human antibody 
structure and its ability of complement activation, the structural 
determinants of mouse antibodies that allow to trigger the cas­
cade are not precisely known.
The best characterized Ig with respect to complement activa­
tion is human IgG1, in which several amino acid residues were 
identified as crucial for the initiation of the complement cascade 
(Figure S6 in Supplementary Material) (19–21). The sequence 
alignment of human IgG1, mouse IgG1, and mouse IgG3 indicated 
that the majority of human IgG1 amino acid residues involved 
in complement activation are conserved in both mouse isotypes 
(Figure S6 in Supplementary Material). However, it revealed two 
differences between mouse IgG1 and IgG3 within the regions cor­
responding to those involved in C1q binding by human IgG1—in 
the N­terminal fragment of the CH2 domain (Val231­Ser238 in 
IgG1 and Ile234­Pro238 in IgG3, EU numbering (22)) and in the 
residue 322 (Figure S6 in Supplementary Material).
To verify whether these motifs are involved in complement 
activation by mouse IgG3, we generated additional muteins in 
which we swapped them between IgG1 and IgG3—IgG1_ILGGP 
(Val231Ile Pro232Leu Glu236Gly Val237Gly Ser238Pro); IgG3_
VPEVS (Ile234Val Leu235Pro Gly236Glu Gly237Val Pro238Ser); 
IgG1_Arg322Lys; IgG3_Lys322Arg, and a double mutein IgG1_
ILGGP_Arg322Lys. The IgG3 heavy chain containing VPEVS did 
not associate with a light chain and was not secreted (Figure 5A). 
Lys322Arg replacement completely abolished complement acti­
vation by IgG3 indicating that Lys322 is crucial for this process 
(Figures 5B,C). The three muteins of IgG1 did not bind C1q nor 
activated complement cascade indicating that the IgG1 framework 
prevents activation of complement (Figures  5B,C). The results 
showed that the known C1q­binding motifs are functional in the 
mouse IgG3 but not in the mouse IgG1 framework.
Some authors observed a correlation between hinge­depend­
ent segmental flexibility of an antibody and its ability to activate 
complement (12). Thus, the differences between activity of mouse 
IgG1 and IgG3 are frequently explained on the basis of the length 
of their hinges. We decided to empirically verify this hypothesis 
using the domain muteins.
First, we analyzed the binding of the complement cascade ini­
tiator (C1q) to the muteins (Figure 6A). The results showed that 
the hinge modification does not affect C1q binding. The swapping 
of the CH2 domain from IgG1 into IgG3 abolished C1q binding 
by the latter. Interestingly, the paired mutein (IgG1_CH2­3) did 
not gain the ability to strongly interact with C1q; its binding of 
C1q reached ~12% of that characteristic for native IgG3. Swapping 
of the CH1 + hinge domains or the CH3 domains between IgG1 
and IgG3 moderately diminished C1q binding by IgG3 and did 
not increase its binding by IgG1.
We also analyzed complement activation in serum triggered 
by erythrocytes coated with the domain muteins (Figure  6B). 
FigUre 5 | Functionality of known C1q-bining motifs in mouse IgG1 and mouse IgG3 frameworks. (a) IgG3_VPEVS did not associate with a light chain and was 
not secreted by the producing cells. (B) C1q binding by the muteins. Plates coated with BSA conjugated with the antigen, B-trisaccharide, were incubated with the 
muteins at 3 µg/ml (O10 variants). Then purified C1q was added. The muteins bind the antigen with different functional affinity. Thus, the C1q signal was normalized 
to the quantity of the bound antibody. Data used for calculation of the normalized binding are shown in Figure S7 in Supplementary Material. Error bars correspond 
to uncertainty calculated as presented in Section “Materials and Methods.” (c) Complement cascade activation by the muteins (3 µg/ml). Erythrocytes coated with 
the antibodies were incubated with complement serum. Complete lysis (100%) corresponds to water-induced lysis. In (a–c) representative results of two 
independent experiments are shown.
9
Klaus and Bereta CH2 Governs Mouse IgG3 Properties
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1096
The levels of erythrocyte lysis indicated that all muteins contain­
ing the CH2 domain derived from IgG3 activate complement 
cascade. The observed differences in C1q binding were not 
reflected by the different efficacy of the cascade triggering. The 
muteins with low (IgG1_CH2­3) or moderate (IgG3_CH1h­1, 
IgG3_CH3­1) ability of C1q­binding activated complement 
cascade with efficacy similar to that of the parental IgG3. It 
seems that in the case of the antibodies comprising IgG3­derived 
CH2 domain, even weak interaction with C1q was sufficient to 
effectively activate the whole complement cascade.
The results showed that both IgG1­ and IgG3­derived CH1, 
hinge, and CH3 domains are permissive for C1q binding and 
complement activation. The CH2 domain of IgG1 is a non­
permissive framework for the known C1q­binding motifs.
Overall, the results pointed to the CH2 domain as the major 
determinant of mouse IgG3 functions and unique properties of 
this isotype. In the last part of our work, we sought for features 
of the IgG3­derived CH2 domain that may account for IgG3 
distinctive characteristic.
Properties of Muteins With reversed 
charge of the ch2 Domains
The most striking difference between mouse IgG3­derived CH2 
and CH2 domains of other IgG subclasses is their charges; only the 
former has a strong positive charge. For example, at pH 7.0, the net 
charge of the CH2 domain of IgG1 is −2.6 and of IgG3 is +2.6 (cal­
culated using http://protcalc.sourceforge.net/). Hovenden et al. (9) 
found a correlation between the charge of CH2 domains of mouse 
IgG subclasses and their affinity to a negatively charged polyvalent 
antigen (poly­glutamic acid, poly­GA); and the high affinity of 
IgG3 to poly­GA was attributed to the charge of its CH2 domain.
We analyzed spatial distribution of charged residues on the CH2 
surface of IgG1 and IgG3 using previously obtained molecular 
models (11) and data deposited in PDB record 1IGY (Figure 7A). 
We identified 29 residues that differ between CH2 domains of 
mouse IgG1 and IgG3, 9 of which have different charge (Figure 
S9 in Supplementary Material). Based on the models, we selected 
four basic residues (His274, Lys282, Arg315, and Lys326) that are 
regularly spaced on the outer surface of the CH2 domain of IgG3 
FigUre 6 | Complement activation induced by the domain muteins. (a) C1q binding to the domain muteins (O10 variants). The data used for calculations  
are presented in Figure S7 in Supplementary Material. Error bars correspond to uncertainty calculated as described in Section “Materials and Methods.”  
(B) Complement cascade activation by the domain muteins. Erythrocytes coated with 3 µg/ml of the muteins were incubated with complement serum.  
100% lysis corresponds to water-induced lysis. The bars present mean values and standard deviation of duplicates from one experiment. Results obtained  
with 1.5 µg/ml of the muteins are presented in Figure S8 in Supplementary Material. (a,B) Representative results of two independent experiments.
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(Figure 7A; Figure S9 in Supplementary Material). The same resi­
dues in IgG1 are not charged. To verify whether CH2 charge influ­
ences IgG3 properties, we generated two muteins in which the four 
residues were swapped—IgG3_CH2charge (His274Gln Lys282Val 
Arg315Asn Lys326Ala) and IgG1_CH2charge (Gln274His 
Val282Lys Asn315Arg Ala326Lys). These muteins were expressed, 
correctly assembled, and soluble (Figure S1 in Supplementary 
Material). The introduced mutations reversed the charge of the 
CH2 domains. It was 0.6 and −0.7 at pH 7.0 for the CH2 domain 
of IgG1_CH2charge and IgG3_CH3charge, respectively.
We compared properties of the parental molecules and the 
muteins with modified CH2 charge. We observed that the charge 
influenced binding to erythrocytes (Figure 7B). However, hemag­
glutination, oligomerization, C1q binding, and complement 
activation were not affected by this charge modification (Table 5; 
Figures 7C–E). The results indicate that the four analyzed resi­
dues have only limited impact on the IgG3 properties. We cannot 
exclude that other charged residues within the CH2 domain of 
IgG3 may influence or determine properties of this isotype.
DiscUssiOn
We summarized the results of the experiments in Table  6. We 
observed that molecular determinants of the unique features of 
IgG3 are present in the CH2 domain. However, the modifications 
of CH2 differently affected the features suggesting that their 
molecular bases are different.
The prominent role of the CH2 domain in IgG3 biology was 
originally reported by Hovenden et  al. (9). The authors inves­
tigated highly protective IgG3 antibodies against the capsular 
antigen of B. anthracis. They generated an IgG3 mutein with 
CH2 swapped from non­protective IgG2b. The mutein lost pro­
tective activity of the parental molecule and had reduced affinity 
to the antigen. In contrast to the work of Hovenden et  al., we 
generated, for the first time, an antibody mutein that gained the 
unique properties of IgG3. We swapped IgG3­derived CH2 into 
IgG1, and the obtained molecule (IgG1_CH2­3) had properties 
typical for IgG3—it agglutinated erythrocytes, oligomerized, 
had increased functional affinity to a polyvalent antigen, and 
activated the complement cascade. Thus, we proved that these 
unique features of mouse IgG3 could be transferred into a new 
antibody framework.
The mechanism of IgG3­dependent hemagglutination is still 
not completely understood. We previously reported that F(ab’)2 of 
IgG3 is sufficient to agglutinate erythrocytes (11). Here, we show 
that the presence of the CH2 domain in the IgG3 molecule pro­
foundly diminishes the antibody concentration required for the 
F(ab’)2­mediated process. Moreover, the introduction of IgG3­
derived CH2 into IgG1 framework resulted in the IgG1_CH2­3 
mutein that agglutinates erythrocytes. The results indicate that 
efficient hemagglutination is triggered only by the antibodies 
equipped with the IgG3­derived CH2 domain.
The CH2 domain of IgG3 is positively charged at neutral pH. In 
contrast, the CH2 domains of other IgG subclasses are negatively 
FigUre 7 | Properties of the muteins with modified charge of the CH2 domain. (a) Charge location on the CH2 domain of IgG1 and IgG3. Basic residues (Arg, His, 
and Lys) are faint red, acidic residues (Asp, Glu) are blue, and a site of CH2 N-glycosylation (Asn297) is green. His274, Lys282, Arg315, and Lys326 of IgG3 CH2 
are dark red. These four residues were swapped between IgG1 and IgG3 to generate IgG1_CH2charge and IgG3_CH2charge muteins. The images present views 
obtained by 90° rotation of the domain models. (B) Antigen binding by the muteins. The charts present representative results of two independent experiments 
performed in duplicates or triplicates. Error bars equal to SD. (c) Oligomerization of the muteins. Results from two independent experiments with 100 µg/ml of the 
antibodies (M18 variants) are shown. A percentage of the total IgG3-biotin detected in precipitates and supernatants are presented in Figure S4 in Supplementary 
Material. Results for IgG1 and IgG3 are the same as in Figure 4 because the data were collected in the same experiments. (D) C1q binding by the muteins (O10 
variants, 3 µg/ml). Data used for calculation of the normalized binding are shown in Figure S7 in Supplementary Material. The chart presents representative results  
of two independent experiments. Error bars correspond to uncertainty calculated as presented in Section “Materials and Methods.” (e) Complement cascade 
activation by the muteins (3 µg/ml). Erythrocytes coated with the antibodies were incubated with complement serum. Complete lysis (100%) corresponds to 
water-induced lysis. Representative results of two independent experiments are shown.
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TaBle 6 | Summary of experimental results.
igg3 feature/function influence by the ch2 domain
Presence net chargea glycosylation
Hemagglutination Strong 
enhancement
No effect Enhancement
Functional affinity to  
polyvalent antigens
Strong 
enhancement
Weak to  
moderate effect
No effect
Oligomerization in solution Dependence No effect No effect
Activation of complement 
cascade
Dependence No effect Dependenceb
aAssociated with the presence of His274, Lys282, Arg315, Lys326.
bData not shown.
TaBle 5 | Hemagglutination induced by the muteins with modified charge of the CH2 domain.
M18 variants O10 variants
conc. (μg/ml) igg1 igg3 igg1_ch2charge igg3_ch2charge conc. (μg/ml) igg1 igg3 igg1_ch2charge igg3_ch2charge
5.00 ±a ++++ – +++ 2.00 – ++++ ± ++++
2.50 – ++++ – +++ 1.00 – +++ – +++
1.25 – +++ – ++ 0.50 – ++ – ++
0.63 – ++ – ++ 0.25 – ± – ±
0.31 – + – ± 0.13 – – – –
0.16 – ± – – 0.06 – – – –
0.00 – – – – 0.00 – – – –
aRepresentative results of two independent experiments.
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charged under the same condition. Considering that erythrocyte 
surface has a strong negative charge and high zeta potential, it 
was likely that a positive charge of the IgG3­derived CH2 domain 
reduces the zeta potential and as a consequence enhances hema­
gglutination. Unexpectedly, net charge modification of the CH2 
domains in IgG1 and IgG3 did not change hemagglutination 
potential of these isotypes, and we had to reject the hypothesis 
linking the CH2 net charge with the efficiency of hemagglutination.
Alternatively, antibody oligomerization may explain hemag­
glutination enhancement by the CH2 domain of IgG3. We showed 
that this domain solely determined antibody oligomerization in 
solution and thus most probably also on a multi­epitope surface. 
It is possible that oligomerization between antibodies bound to 
separate erythrocytes occurs parallel to a sensitization phase of 
hemagglutination. Thus, antibody oligomerization may lead to 
the formation of zipper­like structures that stabilize cell aggre­
gates and increase a hemagglutination score. Moreover, the CH2 
domain of IgG3 increased functional affinity of an antibody to 
erythrocyte surface. Thus, hemagglutination enhancement may 
at least partially depend on the increased affinity.
However, the observed enhancement of hemagglutination 
by the CH2 domain of IgG3 was affected by enzymatic deglyco­
sylation. In contrast, oligomerization in solution and increased 
functional affinity to polyvalent antigen were independent 
of CH2 glycosylation. This difference indicates that antibody 
oligomerization does not fully account for the CH2 domain­
mediated enhancement of hemagglutination.
Mouse IgG3 has a putative site of N­glycosylation in its CH3 
domain on Asn471. Panka reported that the mutation of this 
Asn residue into Ser diminished the self­association of IgG3 
(17). This finding was later contradicted by Kuroki et al., who 
provided evidence that this putative N­glycosylation site in the 
CH3 domain is not occupied and the mutation Asn471Thr does 
not influence IgG3 self­association or cryoglobulin activity (18). 
Our observations are in line with the findings of Kuroki et al. 
We did not observe any differences between oligomerization of 
IgG3 and its enzymatically deglycosylated variant. It is impor­
tant to note that we and Kuroki et  al. used PEG­precipitation 
for oligomerization analyses. Panka used different methods, 
ELISA and native electrophoresis, which may account for the 
discrepancies.
Greenspan et  al. showed that Fc­dependent oligomerization 
increases functional affinity of IgG3 to polyvalent antigens (5). 
Our results confirm that finding, but we showed that the rela­
tion between oligomerization and increased functional affinity is 
more complex than previously thought. First, functional affinity 
of IgG3 was influenced not only by Fc region (CH2 and CH3 
domains) but also by the CH1 domain. Second, functional affinity 
to the polyvalent antigen (B antigen) was modulated by the CH2 
charge. In contrast, oligomerization in solution required only the 
presence of the CH2 domain of IgG3 and was insensitive to 
the introduced charge modifications. The results showed that 
the mechanism behind high functional affinity may depend on 
more factors than oligomerization in solution does.
The observed influence of the CH1 domain on functional 
affinity is difficult to explain. The CH1 domain of IgG3 has a more 
positive net charge than the CH1 domain of IgG1 (9). It is likely 
that the net charge of the CH1 domain influences the binding of 
the domain muteins to erythrocytes, which have a strong negative 
charge. However, the IgG3­derived CH1 domain also enhanced 
the binding of IgG1_CH1­3 to a surface with the immobilized 
trisaccharide B­BSA conjugate. Thus, the results support previous 
observations (23) that the CH1 domain may influence a variable 
domain and a paratope of an antibody.
According to the general view, the Fab and Fc fragments are 
independent parts of an antibody (24). However, our results dem­
onstrate that the Fc, particularly its CH2 domain, may influence 
Fab­mediated antigen binding. There are two possible mechanisms 
of this phenomenon—intramolecular signaling (25) [called by 
some authors as an intramolecular allostery (16)] or intermolecu­
lar cooperativity.
There are several examples of intramolecular signaling 
observed by different authors investigating how the isotype 
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switching changes an antibody affinity to its antigen [reviewed in 
Ref. (16, 26)]. The effects of the CH1 domains or Fc fragments on 
variable regions are well documented, but considered a rather 
unique phenomenon (16). It is more likely that the increased 
affinity of IgG3 to its antigen results from cooperativity of its CH2 
domains. Within this domain, a specific site of self­association may 
be present, which governs oligomerization of an antibody and pre­
determines the increased affinity to multivalent antigens. However, 
we cannot exclude other scenarios—the involvement of both the 
CH2 and CH3 domains in IgG3 intermolecular interactions or 
even sole CH3­CH3 interactions, assuming that the CH2 domains 
influence the whole molecule structure and promote reciprocal 
interactions of the CH3 domains of neighboring molecules.
Other factors, e.g., influence of the CH1 domain on a paratope, 
properties of an antigen (charge), spatial distribution of epitopes, 
intermolecular forces between epitope and paratope, or a variable 
domain framework may further modulate functional affinity of 
IgG3 upon multivalent antigen binding.
Diebolder at al. described recently an interesting example of 
Fc­dependent antibody oligomerization. Analyses of antibody 
binding to DNP­labeled liposomes (a multivalent antigen) revealed 
that human IgG may form hexamers through non­covalent 
interactions between their constant regions (27). Several muta­
tions that enhance these interactions and subsequent complement 
activation were reported (27). The Fc­interactions promoting 
antibody hexamerization did not change affinity to the cognate 
antigen. Thus, this phenomenon seems to be different from IgG3 
oligomerization, and it is still an open question whether mouse 
antibodies are able to form such hexamers.
Currently, no structure is available for a full­length mouse 
IgG3 or its Fc fragment. We performed some analyses using a 
molecular model of IgG3 obtained by comparative modeling, but 
its resolution is not sufficient for in­depth studies. IgG3 crystal­
lization might provide a direct insight into the mechanism of its 
oligomerization, as was in the case of human IgG1 hexameriza­
tion described in the cited work (27).
Complement cascade activation, as an effector function of 
antibodies, constitutes a first­line of defense against microbial 
infections. As the cascade progresses, components of the comple­
ment are deposited on a pathogen surface and act as opsonins 
for phagocytic cells. Moreover, the complement lyses invading 
pathogens by forming membrane attacking complex. We con­
firmed that C1q­binding motifs, known from human IgG1, are 
functional in the mouse IgG3 framework. On the other hand, we 
did not observe complement activation by mouse IgG1 equipped 
with the motifs. The results indicate that the presence of the known 
C1q­binding motifs is not sufficient for complement activation 
by an antibody. The motifs must be surrounded by a permissive 
framework, provided e.g., by human IgG1 or mouse IgG3.
Our work suggests that a novel type of monoclonal antibod­
ies may be generated by replacing the CH2 domain of a human 
antibody with the homologs fragment of mouse IgG3. Human 
IgG1 subclass is the most feasible target framework for gen­
eration of such IgG3­inspired hybrid mouse/human molecule 
(28). Our observation indicates that the generated hybrid anti­
body should preserve the ability to activate complement and 
may have increased affinity to polyvalent antigens. Since the 
mouse IgG3 subclass is highly protective against several life­ 
threatening microbial infections, the hybrid molecule may be 
very useful in preventing or fighting lethal pathogens. However, 
the hybrid antibody with the mouse CH2 may be immuno­
genic. To decrease the risk of an unwanted immune response, 
the mouse component should be reduced to a minimum. Thus, 
the properties of the CH2 domain derived from mouse IgG3 
should be further investigated and efforts should be made espe­
cially to identify fragments of this domain that determines its 
properties.
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